

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

20-154 / S-049

20-155 / S-038

20-156 / S-039

20-183 / S-015

Trade Name: Videx

Generic Name: Didanosine

Sponsor: Bristol-Myers Squibb

Approval Date: August 8, 2006

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-154 / S-049

20-155 / S-038

20-156 / S-039

20-183 / S-015

APPROVAL LETTER

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-154 / S-049

20-155 / S-038

20-156 / S-039

20-183 / S-015

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	



NDA 20-154/S-049
NDA 20-155/S-038 ✓
NDA 20-156/S-039 ✓
NDA 21-183/S-015

CHANGES BEING EFFECTED

Bristol-Myers Squibb Pharmaceutical Company
Attention: Nancy Mason-Liddil
Associate Director, Global Regulatory Sciences
5 Research Parkway
Signature 91 Building, 3SIG-513
Wallingford, CT 06492

Dear Ms. Mason-Liddil:

Please refer to your supplemental new drug applications dated January 27, 2006 received January 30, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following products:

- Videx[®] (didanosine) Chewable/Dispersible Buffered Tablets 25 mg, 50 mg, 100 mg, 150mg, and 200 mg
- Videx[®] (didanosine) Buffered Powder for Oral Solution 45 mg, 67mg, 100 mg, 167 mg, 250 mg, and 375 mg
- Videx[®] (didanosine) Pediatric Powder for Oral Solution 2mg/bottle, and 4gm/bottle
- Videx[®] EC (didanosine) Delayed Release Capsules 125 mg, 200 mg, 250 mg, and 400 mg

We acknowledge receipt of your amendments dated July 31, 2006.

These "Changes Being Effected" supplemental new drug applications provide the addition of the statement regarding immune reconstitution syndrome in the PRECAUTIONS section of the package insert for Videx[®] and Videx EC[®] in response to a request from the FDA. In addition, the following labeling changes are made:

- Adding a warning statement regarding patients with preexisting liver disease
- Adding a warning/precaution statement regarding adverse events when coadministered with hydroxyurea
- Deleting Extra Strength Maalox[®] from the Method of Preparation (only for Videx[®])
- Revising the cautionary statement for tenofovir/didanosine coadministration to add monitoring for clinical response

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

We completed our review of these supplemental new drug applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on July 31, 2006.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Monica Zeballos, Pharm.D., Regulatory Project Manager, at (301) 796-0840.

Sincerely yours,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Approved labeling (package insert and patient package insert) for Videx[®] and Videx EC[®]

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Debra Birnkrant
8/18/2006 01:19:27 PM
NDA 21-183, 20-156, 20-155, 20-154

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-154 / S-049

20-155 / S-038

20-156 / S-039

20-183 / S-015

LABELING

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Rx only

VIDEX[®] (didanosine)

VIDEX[®] (didanosine) Chewable/Dispersible Buffered Tablets

VIDEX[®] (didanosine) Pediatric Powder for Oral Solution

(Patient Information Leaflet Included)

WARNING

FATAL AND NONFATAL PANCREATITIS HAVE OCCURRED DURING THERAPY WITH VIDEX USED ALONE OR IN COMBINATION REGIMENS IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, REGARDLESS OF DEGREE OF IMMUNOSUPPRESSION. VIDEX SHOULD BE SUSPENDED IN PATIENTS WITH SUSPECTED PANCREATITIS AND DISCONTINUED IN PATIENTS WITH CONFIRMED PANCREATITIS (SEE WARNINGS).

LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES ALONE OR IN COMBINATION, INCLUDING DIDANOSINE AND OTHER ANTIRETROVIRALS. FATAL LACTIC ACIDOSIS HAS BEEN REPORTED IN PREGNANT WOMEN WHO RECEIVED THE COMBINATION OF DIDANOSINE AND STAVUDINE WITH OTHER ANTIRETROVIRAL AGENTS. THE COMBINATION OF DIDANOSINE AND STAVUDINE SHOULD BE USED WITH CAUTION DURING PREGNANCY AND IS RECOMMENDED ONLY IF THE POTENTIAL BENEFIT CLEARLY OUTWEIGHS THE POTENTIAL RISK (SEE WARNINGS AND PRECAUTIONS: PREGNANCY).

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015


DESCRIPTION

VIDEX[®] (didanosine) is a brand name for didanosine (ddI), a synthetic purine nucleoside analogue active against the Human Immunodeficiency Virus (HIV). VIDEX Chewable/Dispersible Buffered Tablets are available for oral administration in strengths of 25, 50, 100, 150, and 200 mg of didanosine. Each tablet is buffered with calcium carbonate and magnesium hydroxide. VIDEX tablets also contain aspartame, sorbitol, microcrystalline cellulose, polyplasdone, mandarin-orange flavor, and magnesium stearate.

VIDEX Pediatric Powder for Oral Solution is supplied for oral administration in 4- or 8-ounce glass bottles containing 2 or 4 grams of didanosine, respectively.

Didanosine is also available as an enteric-coated formulation (VIDEX[®] EC Delayed-Release Capsules). Please consult the prescribing information for VIDEX EC (didanosine).

The chemical name for didanosine is 2',3'-dideoxyinosine. The structural formula is:



Didanosine is a white crystalline powder with the molecular formula $C_{10}H_{12}N_4O_3$ and a molecular weight of 236.2. The aqueous solubility of didanosine at 25° C and pH of approximately 6 is 27.3 mg/mL. Didanosine is unstable in acidic solutions. For example, at pH <3 and 37° C, 10% of didanosine decomposes to hypoxanthine in less than 2 minutes.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

MICROBIOLOGY

Mechanism of Action

Didanosine is a synthetic nucleoside analogue of the naturally occurring nucleoside deoxyadenosine in which the 3'-hydroxyl group is replaced by hydrogen. Intracellularly, didanosine is converted by cellular enzymes to the active metabolite, dideoxyadenosine 5'-triphosphate. Dideoxyadenosine 5'-triphosphate inhibits the activity of HIV-1 reverse transcriptase both by competing with the natural substrate, deoxyadenosine 5'-triphosphate, and by its incorporation into viral DNA causing termination of viral DNA chain elongation.

***In Vitro* HIV Susceptibility**

The *in vitro* anti-HIV-1 activity of didanosine was evaluated in a variety of HIV-1 infected lymphoblastic cell lines and monocyte/macrophage cell cultures. The concentration of drug necessary to inhibit viral replication by 50% (IC₅₀) ranged from 2.5 to 10 μM (1 μM = 0.24 μg/mL) in lymphoblastic cell lines and 0.01 to 0.1 μM in monocyte/macrophage cell cultures. The relationship between *in vitro* susceptibility of HIV to didanosine and the inhibition of HIV replication in humans has not been established.

Drug Resistance

HIV-1 isolates with reduced sensitivity to didanosine have been selected *in vitro* and were also obtained from patients treated with didanosine. Genetic analysis of isolates from didanosine-treated patients showed mutations in the reverse transcriptase gene that resulted in the amino acid substitutions K65R, L74V, and M184V. The L74V mutation was most frequently observed in clinical isolates. Phenotypic analysis of HIV-1 isolates from 60 patients (some with prior zidovudine treatment) receiving 6 to 24 months of didanosine monotherapy showed that isolates from 10 of 60 patients exhibited an average of a 10-fold decrease in susceptibility to didanosine *in vitro* compared to baseline isolates. Clinical isolates that exhibited a decrease in didanosine susceptibility harbored one or more didanosine-associated mutations. The clinical relevance of genotypic and phenotypic changes associated with didanosine therapy has not been established.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Cross-resistance

HIV-1 isolates from 2 of 39 patients receiving combination therapy for up to 2 years with zidovudine and didanosine exhibited decreased susceptibility to zidovudine, didanosine, zalcitabine, stavudine, and lamivudine *in vitro*. These isolates harbored five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the reverse transcriptase gene. The clinical relevance of these observations has not been established.

CLINICAL PHARMACOLOGY

Animal Toxicology

Evidence of a dose-limiting skeletal muscle toxicity has been observed in mice and rats (but not in dogs) following long-term (greater than 90 days) dosing with didanosine at doses that were approximately 1.2 to 12 times the estimated human exposure. The relationship of this finding to the potential of VIDEX (didanosine) to cause myopathy in humans is unclear. However, human myopathy has been associated with administration of VIDEX and other nucleoside analogues.

Pharmacokinetics

The pharmacokinetic parameters of didanosine are summarized in Table 1. Didanosine is rapidly absorbed, with peak plasma concentrations generally observed from 0.25 to 1.50 hours following oral dosing. Increases in plasma didanosine concentrations were dose proportional over the range of 50 to 400 mg. Steady-state pharmacokinetic parameters did not differ significantly from values obtained after a single dose. Binding of didanosine to plasma proteins *in vitro* was low (<5%). Based on data from *in vitro* and animal studies, it is presumed that the metabolism of didanosine in man occurs by the same pathways responsible for the elimination of endogenous purines.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 1: Mean ± SD Pharmacokinetic Parameters for Didanosine in Adult and Pediatric Patients

Parameter	Adult Patients ^a		Pediatric Patients ^b			
	Mean ± SD	n	8 months to 19 years	n	2 weeks to 4 months	n
Oral bioavailability (%)	42 ± 12	6	25 ± 20	46	ND	
Apparent volume of distribution ^c (L/m ²)	43.70 ± 8.90	6	28 ± 15	49	ND	
CSF-plasma ratio ^d	21 ± 0.03% ^e	5	46% (range 12-85%)	7	ND	
Systemic clearance ^c (mL/min/m ²)	526 ± 64.7	6	516 ± 184	49	ND	
Renal clearance ^f (mL/min/m ²)	223 ± 85.0	6	240 ± 90	15	ND	
Apparent oral clearance ^g (mL/min/m ²)	1252 ± 154	6	2064 ± 736	48	1353 ± 759	41
Elimination half-life ^f (h)	1.5 ± 0.4	6	0.8 ± 0.3	60	1.2 ± 0.3	21
Urinary recovery of didanosine ^f (%)	18 ± 8	6	18 ± 10	15	ND	

CSF = cerebrospinal fluid, ND = not determined.

^a Parameter units for adults were converted to the same units in pediatric patients to facilitate comparisons among populations: mean adult body weight = 70 kg and mean adult body surface area = 1.73 m².

^b In 1-day old infants (n=10), the mean ± SD apparent oral clearance was 1523 ± 1176 mL/min/m² and half-life was 2.0 ± 0.7 h.

^c Following IV administration.

^d Following IV administration in adults and IV or oral administration in pediatric patients.

^e Mean ± SE.

^f Following oral administration.

^g Apparent oral clearance estimate was determined as the ratio of the mean systemic clearance and the mean oral bioavailability estimate.

Effect of Food on Absorption of Didanosine: Didanosine peak plasma concentrations (C_{MAX}) and area under the plasma concentration time curve (AUC) were decreased by approximately 55% when VIDEX tablets were administered up to 2 hours after a meal. Administration of VIDEX tablets up to 30 minutes before a meal did not result in any significant changes in bioavailability. VIDEX should be taken on an empty stomach, at least 30 minutes before or 2 hours after eating. (See **DOSAGE AND ADMINISTRATION.**)

Special Populations

Renal Insufficiency: It is recommended that the VIDEX (didanosine) dose be modified in patients with reduced creatinine clearance and in patients receiving maintenance hemodialysis (see **DOSAGE AND ADMINISTRATION**). Data from two studies in adults indicated that the apparent oral clearance of didanosine decreased and the terminal elimination half-life increased as creatinine clearance decreased (see Table 2). Following oral administration, didanosine was not detectable in peritoneal dialysate fluid (n=6); recovery in hemodialysate (n=5) ranged from 0.6% to 7.4% of the dose over a 3-4 hour dialysis period. The absolute bioavailability of didanosine was not affected in patients requiring dialysis.

Table 2: Mean ± SD Pharmacokinetic Parameters for Didanosine Following a Single Oral Dose

Parameter	Creatinine Clearance (mL/min)				Dialysis Patients (n=11)
	≥ 90 (n=12)	60-90 (n=6)	30-59 (n=6)	10-29 (n=3)	
CL _{cr} (mL/min)	112 ± 22	68 ± 8	46 ± 8	13 ± 5	ND
CL/F (mL/min)	2164 ± 638	1566 ± 833	1023 ± 378	628 ± 104	543 ± 174
CL _R (mL/min)	458 ± 164	247 ± 153	100 ± 44	20 ± 8	<10
T _½ (h)	1.42 ± 0.33	1.59 ± 0.13	1.75 ± 0.43	2.0 ± 0.3	4.1 ± 1.2

ND = not determined due to anuria.
 CL_{cr} = creatinine clearance.
 CL/F = apparent oral clearance.
 CL_R = renal clearance.

Pediatric Patients: The pharmacokinetics of didanosine have been evaluated in HIV-exposed and -infected pediatric patients from birth to 19 years of age (see Table 1). Overall, the pharmacokinetics of didanosine in pediatric patients are similar to those of didanosine in adults. Didanosine plasma concentrations appear to increase in proportion to oral doses ranging from 25 to 120 mg/m² in pediatric patients less than 5 months old and from 80 to 180 mg/m² in children above 8 months old. For information on controlled clinical studies in pediatric patients, see **INDICATIONS AND USAGE: Clinical Studies** and **PRECAUTIONS: Pediatric Use**.

Geriatric Patients: Didanosine pharmacokinetics have not been studied in patients over 65 years of age.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Gender: The effects of gender on didanosine pharmacokinetics have not been studied.

Drug Interactions: Ribavirin has been shown *in vitro* to increase intracellular triphosphate levels of didanosine, which could cause or worsen clinical toxicities (see **PRECAUTIONS: Drug Interactions**).

Tables 3 and 4 summarize the effects on AUC and C_{MAX} , with a 90% or 95% confidence interval (CI) when available, following coadministration of VIDEX with a variety of drugs. For most of the listed drugs, no clinically significant pharmacokinetic interactions were observed. Clinical recommendations based on drug interaction studies for drugs in bold font are included in **PRECAUTIONS: Drug Interactions** and **DOSAGE AND ADMINISTRATION** (for tenofovir).

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 3: Results of Drug Interaction Studies with VIDEX: Effects of Coadministered Drug on Didanosine Plasma AUC and C_{MAX} Values

<i>Drugs With Clinical Recommendations Regarding Coadministration (see PRECAUTIONS: Drug Interactions)</i>				
Drug	Didanosine Dosage	n	AUC of Didanosine (95% CI)	C _{MAX} of Didanosine (95% CI)
allopurinol				
renally impaired, 300 mg/day	200 mg single dose	2	↑ 312%	↑ 232%
healthy volunteer, 300 mg/day for 7 days	400 mg single dose	14	↑ 113%	↑ 69%
ciprofloxacin , 750 mg q12h for 3 days, 2 h before didanosine	200 mg q12h for 3 days	8 ^a	↓ 16%	↓ 28%
ganciclovir , 1000 mg q8h, 2 h after didanosine	200 mg q12h	12	↑ 111%	NA
indinavir , 800 mg single dose simultaneous				
	200 mg single dose	16	↔	↔
1 h before didanosine	200 mg single dose	16	↓ 17% (-27, -7%) ^b	↓ 13% (-28, 5%) ^b
ketoconazole , 200 mg/day for 4 days, 2 h before didanosine	375 mg q12h for 4 days	12 ^a	↔	↓ 12%
methadone , chronic maintenance dose	200 mg single dose	16, 10 ^c	↓ 57%	↓ 66%
tenofovir , ^{d,e} 300 mg once daily 1 h after didanosine	250 ^f or 400 mg once daily for 7 days	14	↑ 44% (31, 59%) ^b	↑ 28% (11, 48%) ^b
<i>No Clinically Significant Interaction Observed</i>				
Drug	Didanosine Dosage	n	AUC of Didanosine (95% CI)	C _{MAX} of Didanosine (95% CI)
loperamide, 4 mg q6h for 1 day	300 mg single dose	12 ^a	↔	↓ 23%
metoclopramide, 10 mg single dose	300 mg single dose	12 ^a	↔	↑ 13%
ranitidine, 150 mg single dose, 2 h before didanosine	375 mg single dose	12 ^a	↑ 14%	↑ 13%
rifabutin, 300 or 600 mg/day for 12 days	167 or 250 mg q12h for 12 days	11	↑ 13% (-1, 27%)	↑ 17% (-4, 38%)
ritonavir, 600 mg q12h for 4 days	200 mg q12h for 4 days	12	↓ 13% (0, 23%)	↓ 16% (5, 26%)
stavudine, 40 mg q12h for 4 days	100 mg q12h for 4 days	10	↔	↔
sulfamethoxazole, 1000 mg single dose	200 mg single dose	8 ^a	↔	↔
trimethoprim, 200 mg single dose	200 mg single dose	8 ^a	↔	↑ 17% (-23, 77%)
zidovudine, 200 mg q8h for 3 days	200 mg q12h for 3 days	6 ^a	↔	↔

↑ indicates increase.
 ↓ indicates decrease.
 ↔ indicates no change, or mean increase or decrease of <10%.
^a HIV-infected patients.
^b 90% CI.
^c Parallel-group design; entries are subjects receiving combination and control regimens, respectively.
^d tenofovir disoproxil fumarate.
^e For results of drug interaction studies between the enteric-coated formulation of didanosine (VIDEX EC) and tenofovir, see the complete prescribing information for VIDEX EC.
^f patients <60 kg with creatinine clearance ≥60 mL/min.
 NA Not available.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 4: Results of Drug Interaction Studies with VIDEX: Effects of Didanosine on Coadministered Drug Plasma AUC and C_{MAX} Values

<i>Drugs With Clinical Recommendations Regarding Coadministration (see PRECAUTIONS: Drug Interactions)</i>				
Drug	Didanosine Dosage	n	AUC of Coadministered Drug (95% CI)	C _{MAX} of Coadministered Drug (95% CI)
ciprofloxacin				
750 mg q12h for 3 days, 2 h before didanosine	200 mg q12h for 3 days	8 ^a	↓ 26%	↓ 16%
750 mg single dose	buffered placebo tablet	12	↓ 98%	↓ 93%
delavirdine, 400 mg single dose				
simultaneous	125 or 200 mg q12h	12 ^a	↓ 32%	↓ 53%
1 h before didanosine	125 or 200 mg q12h	12 ^a	↑ 20%	↑ 18%
ganciclovir, 1000 mg q8h, 2 h after didanosine				
	200 mg q12h	12 ^a	↓ 21%	NA
indinavir, 800 mg single dose				
simultaneous	200 mg single dose	16	↓ 84%	↓ 82%
1 h before didanosine	200 mg single dose	16	↓ 11%	↓ 4%
ketconazole, 200 mg/day for 4 days, 2 h before didanosine				
	375 mg q12h for 4 days	12 ^a	↓ 14%	↓ 20%
nelfinavir, 750 mg single dose, 1 h after didanosine				
	200 mg single dose	10 ^a	↑ 12%	↔
No Clinically Significant Interaction Observed				
Drug	Didanosine Dosage	n	AUC of Coadministered Drug (95% CI)	C _{MAX} of Coadministered Drug (95% CI)
dapsone, 100 mg single dose	200 mg q12h for 14 days	6 ^a	↔	↔
ranitidine, 150 mg single dose, 2 h before didanosine	375 mg single dose	12 ^a	↓ 16%	↔
ritonavir, 600 mg q12h for 4 days	200 mg q12h for 4 days	12	↔	↔
stavudine, 40 mg q12h for 4 days	100 mg q12h for 4 days	10 ^a	↔	↑ 17%
sulfamethoxazole, 1000 mg single dose	200 mg single dose	8 ^a	↓ 11% (-17, -4%)	↓ 12% (-28, 8%)
tenofovir, ^b 300 mg once daily 1 h after didanosine	250 ^c or 400 mg once daily for 7 days	14	↔	↔
trimethoprim, 200 mg single dose	200 mg single dose	8 ^a	↑ 10% (-9, 34%)	↓ 22% (-59, 49%)
zidovudine, 200 mg q8h for 3 days	200 mg q12h for 3 days	6 ^a	↓ 10% (-27, 11%)	↓ 16.5% (-53, 47%)

↑ indicates increase.
 ↓ indicates decrease.
 ↔ indicates no change, or mean increase or decrease of <10%.
^a HIV-infected patients.
^b tenofovir disoproxil fumarate.
^c patients <60 kg with creatinine clearance ≥60 mL/min.
 NA Not available.

INDICATIONS AND USAGE

VIDEX (didanosine) in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection (see Clinical Studies).


Clinical Studies

Combination Therapy

START 2 was a multicenter, randomized, open-label study comparing VIDEX (200 mg twice daily)/stavudine/indinavir to zidovudine/lamivudine/indinavir in 205 treatment-naive patients. Both regimens resulted in a similar magnitude of suppression of HIV RNA levels and increases in CD4 cell counts through 48 weeks.

Study A1454-148 was a randomized, open-label, multicenter study comparing treatment with VIDEX (400 mg once daily) plus stavudine (40 mg twice daily) and nelfinavir (750 mg three times daily) versus zidovudine (300 mg twice daily) plus lamivudine (150 mg twice daily) and nelfinavir (750 mg three times daily) in 756 treatment-naive patients, with a median CD4 cell count of 340 cells/mm³ (range 80 to 1568 cells/mm³) and a median plasma HIV-1 RNA of 4.69 log₁₀ copies/mL (range 2.6 to 5.9 log₁₀ copies/mL) at baseline. Median CD4 cell count increases at 48 weeks were 188 cells/mm³ in both treatment groups. Treatment response and outcomes through 48 weeks are shown in Figure 1 and Table 5.

Figure 1: Treatment Response Through Week 48*, A1454-148



* Percent of patients at each time point who have HIV RNA <400 or <50 copies/mL, are on their original study medication (except stavudine-zidovudine switches), and have not experienced an AIDS-defining event.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 5: Outcomes of Randomized Treatment through Week 48, AI454-148

Week 48 Status	Percent of Patients with HIV RNA <400 copies/mL (<50 copies/mL)	
	VIDEX/stavudine/nelfinavir n=503	lamivudine/zidovudine/nelfinavir n=253
Responder ^a	50* (34*)	59 (47)
Virologic failure ^b	36 (57)	32 (48)
Death or disease progression	<1 (<1)	1 (<1)
Discontinued due to adverse events	4 (2)	2 (<1)
Discontinued due to other reasons ^c	6 (3)	4 (2)
Never initiated treatment	4 (4)	2 (2)

* p <0.05 for the differences between treatment groups, by Cochran-Mantel-Haenszel test.
^a Patients achieved virologic response [two consecutive viral loads <400 (<50) copies/mL] and maintained it to Week 48.
^b Includes viral rebound and failing to achieve confirmed <400 (<50) copies/mL by Week 48.
^c Includes lost to follow-up, noncompliance, withdrawal, and pregnancy.

Monotherapy

The efficacy of VIDEX was demonstrated in two randomized, double-blind studies comparing VIDEX, given on a twice-daily schedule, to zidovudine, given three times daily, in 617 (ACTG 116A, conducted 1989-1992) and 913 (ACTG 116B/117, conducted 1989-1991) patients with symptomatic HIV infection or AIDS who were treated for more than one year. In treatment-naïve patients (ACTG 116A), the rate of HIV disease progression or death was similar between the treatment groups; mortality rates were 26% for patients receiving VIDEX and 21% for patients receiving zidovudine. Of the patients who had received previous zidovudine treatment (ACTG 116B/117), those treated with VIDEX had a lower rate of HIV disease progression or death (32%) compared to those treated with zidovudine (41%); however, survival rates were similar between the treatment groups.

Efficacy in pediatric patients was demonstrated in a randomized, double-blind, controlled study (ACTG 152, conducted 1991-1995) involving 831 patients 3 months to 18 years of age treated for more than 1.5 years with zidovudine (180 mg/m² q6h), VIDEX (120 mg/m² q12h), or zidovudine (120 mg/m² q6h) plus VIDEX (90 mg/m² q12h). Patients treated with VIDEX or VIDEX plus zidovudine had lower rates of HIV disease progression or death compared with those treated with zidovudine alone.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Studies have demonstrated that the clinical benefit of monotherapy with antiretrovirals, including VIDEX, was time limited.

CONTRAINDICATION

VIDEX (didanosine) is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of the formulations.

WARNINGS

1. Pancreatitis

FATAL AND NONFATAL PANCREATITIS HAVE OCCURRED DURING THERAPY WITH VIDEX USED ALONE OR IN COMBINATION REGIMENS IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, REGARDLESS OF DEGREE OF IMMUNOSUPPRESSION. VIDEX SHOULD BE SUSPENDED IN PATIENTS WITH SIGNS OR SYMPTOMS OF PANCREATITIS AND DISCONTINUED IN PATIENTS WITH CONFIRMED PANCREATITIS. PATIENTS TREATED WITH VIDEX IN COMBINATION WITH STAVUDINE, WITH OR WITHOUT HYDROXYUREA, MAY BE AT INCREASED RISK FOR PANCREATITIS.

When treatment with life-sustaining drugs known to cause pancreatic toxicity is required, suspension of VIDEX (didanosine) therapy is recommended. In patients with risk factors for pancreatitis, VIDEX should be used with extreme caution and only if clearly indicated. Patients with advanced HIV infection, especially the elderly, are at increased risk of pancreatitis and should be followed closely. Patients with renal impairment may be at greater risk for pancreatitis if treated without dose adjustment.

The frequency of pancreatitis is dose related. In phase 3 studies, incidence ranged from 1% to 10% with doses higher than are currently recommended and 1% to 7% with recommended dose.

In pediatric phase 1 studies, pancreatitis occurred in 3% (2/60) of patients treated at entry doses below 300 mg/m²/day and in 13% (5/38) of patients treated at higher doses. In study ACTG 152, pancreatitis occurred in none of the 281 pediatric patients who received didanosine 120 mg/m² q12h and in <1% of the 274 pediatric patients who received

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

didanosine 90 mg/m² q12h in combination with zidovudine. VIDEX (didanosine) use should be suspended in pediatric patients with signs or symptoms of pancreatitis and discontinued in pediatric patients with confirmed pancreatitis.

2. Lactic Acidosis/Severe Hepatomegaly with Steatosis

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including didanosine and other antiretrovirals. A majority of these cases have been in women. Obesity and prolonged nucleoside exposure may be risk factors. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk (see **PRECAUTIONS: Pregnancy**). Particular caution should be exercised when administering VIDEX to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with VIDEX should be suspended in any patient who develops clinical or laboratory findings suggestive of symptomatic hyperlactatemia, lactic acidosis, or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

3. Retinal Changes and Optic Neuritis

Retinal changes and optic neuritis have been reported in adult and pediatric patients. Periodic retinal examinations should be considered for patients receiving VIDEX. (See **ADVERSE REACTIONS**.)

4. Hepatic Impairment and Toxicity

It is unknown if hepatic impairment significantly affects didanosine pharmacokinetics. Therefore, these patients should be monitored closely for evidence of didanosine toxicity. The safety and efficacy of VIDEX have not been established in HIV-infected patients with significant underlying liver disease. During combination antiretroviral therapy, patients with preexisting liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities, including severe and potentially fatal hepatic adverse events, and should be monitored according to standard

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.

Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV-infected patients treated with hydroxyurea and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. This combination should be avoided.

PRECAUTIONS

Frequency of Dosing

The preferred dosing frequency of VIDEX is twice daily because there is more evidence to support the effectiveness of this dosing frequency. Once-daily dosing should be considered only for adult patients whose management requires once-daily dosing of VIDEX (see **INDICATIONS AND USAGE: Clinical Studies**).

VIDEX should be taken on an empty stomach, at least 30 minutes before or 2 hours after eating.

Peripheral Neuropathy

Peripheral neuropathy, manifested by numbness, tingling, or pain in the hands or feet, has been reported in patients receiving VIDEX therapy. Peripheral neuropathy has occurred more frequently in patients with advanced HIV disease, in patients with a history of neuropathy, or in patients being treated with neurotoxic drug therapy, including stavudine. Peripheral neuropathy, which was severe in some cases, has been reported in HIV-infected patients receiving hydroxyurea in combination with antiretroviral agents, including didanosine, with or without stavudine (see **ADVERSE REACTIONS**).

Fat Redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including VIDEX. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jiroveci* pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

General

Patients with Phenylketonuria: VIDEX Chewable/Dispersible Buffered Tablets contain the following quantities of phenylalanine:

Table 6

	All Strengths
Phenylalanine per 2-tablet dose	73 mg
Phenylalanine per tablet	36.5 mg

Patients with Renal Impairment: Patients with renal impairment (creatinine clearance <60 mL/min) may be at greater risk of toxicity from VIDEX due to decreased drug clearance (see **CLINICAL PHARMACOLOGY**). A dose reduction is recommended in these patients (see **DOSAGE AND ADMINISTRATION**). The magnesium content of each buffered tablet of VIDEX is 8.6 mEq. This may present an excessive load of magnesium to patients with significant renal impairment, particularly after prolonged dosing.

Hyperuricemia: VIDEX has been associated with asymptomatic hyperuricemia; treatment suspension may be necessary if clinical measures aimed at reducing uric acid levels fail.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Information for Patients (see Patient Information Leaflet)

Patients should be informed that a serious toxicity of VIDEX used alone and in combination regimens is pancreatitis, which may be fatal.

Patients should be informed that the preferred dosing frequency of VIDEX is twice daily because there is more evidence to support the effectiveness of this dosing frequency. Once-daily dosing should be considered only for adult patients whose management requires once-daily dosing of VIDEX.

Patients should also be aware that peripheral neuropathy, manifested by numbness, tingling, or pain in hands or feet, may develop during therapy with VIDEX. Patients should be counseled that peripheral neuropathy occurs with greatest frequency in patients with advanced HIV disease or a history of peripheral neuropathy, and that dose modification and/or discontinuation of VIDEX may be required if toxicity develops.

Patients should be informed that when VIDEX is used in combination with other agents with similar toxicities, the incidence of adverse events may be higher than when VIDEX is used alone. These patients should be followed closely.

Patients should be cautioned about the use of medications or other substances, including alcohol, that may exacerbate VIDEX toxicities.

Patients should be advised that to ensure proper acid neutralization in the stomach they must take at least two of the appropriate strength VIDEX tablets at each dose. To reduce the risk of gastrointestinal side effects from excess antacid, patients should take no more than four VIDEX tablets at each dose.

VIDEX (didanosine) is not a cure for HIV infection, and patients may continue to develop HIV-associated illnesses, including opportunistic infection. Therefore, patients should remain under the care of a physician when using VIDEX. Patients should be advised that VIDEX therapy has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination. Patients should be informed that the long-term effects of VIDEX are unknown at this time.

Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time.

Drug Interactions (see also CLINICAL PHARMACOLOGY: Drug Interactions)

Drug interactions that have been established based on drug interaction studies are listed with the pharmacokinetic results in **CLINICAL PHARMACOLOGY: Drug Interactions** (Tables 3 and 4). The clinical recommendations based on the results of these studies are listed in Table 7.

Table 7: Established Drug Interactions with VIDEX

<i>Coadministration Not Recommended Based on Drug Interaction Studies (see CLINICAL PHARMACOLOGY: Drug Interactions for Magnitude of Interaction)</i>		
Drug	Effect	Clinical Comment
allopurinol	↑ didanosine concentration	Coadministration not recommended.
<i>Alteration in Dose or Regimen Recommended Based on Drug Interaction Studies (see CLINICAL PHARMACOLOGY: Drug Interactions for Magnitude of Interaction)</i>		
Drug	Effect	Clinical Comment
ciprofloxacin	↓ ciprofloxacin concentration	Administer VIDEX at least 2 hours after or 6 hours before ciprofloxacin.
delavirdine	↓ delavirdine concentration	Administer VIDEX 1 hour after delavirdine.
ganciclovir	↑ didanosine concentration	Appropriate doses for this combination, with respect to efficacy and safety, have not been established.
indinavir	↓ indinavir concentration	Administer VIDEX 1 hour after indinavir.
methadone	↓ didanosine concentration	Appropriate doses for this combination, with respect to efficacy and safety, have not been established.
nelfinavir	No interaction 1 hour after didanosine	Administer nelfinavir 1 hour after VIDEX.
tenofovir disoproxil fumarate	↑ didanosine concentration	A dose reduction of VIDEX to 250 mg (adults weighing ≥60 kg with creatinine clearance ≥60 mL/min) or 200 mg (adults weighing <60 kg with creatinine clearance ≥60 mL/min) once daily is recommended. VIDEX and tenofovir may be taken together in the fasted state. Alternatively, if tenofovir is taken with food, VIDEX should be taken on an empty stomach (at least 30 minutes before food or 2 hours after food). Patients should be monitored for didanosine-associated toxicities and clinical response (see below).

↑ indicates increase.
 ↓ indicates decrease.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Coadministration of VIDEX with drugs that are known to cause pancreatitis may increase the risk of this toxicity (see WARNINGS: Pancreatitis). Because VIDEX formulations either contain buffers or are mixed with antacids before administration, interactions may be anticipated with drugs whose absorption can be affected by the level of acidity in the stomach and with drugs that have been demonstrated to interact with antacids containing magnesium, calcium, or aluminum. Predicted drug interactions with VIDEX are listed in Table 8.

Table 8: Predicted Drug Interactions with VIDEX

<i>Use with Caution or Not Recommended, Risk of Adverse Reactions May Be Increased</i>		
Drug or Drug Class	Effect	Clinical Comment
Drugs that may cause pancreatic toxicity	↑ risk of pancreatitis	Use only with extreme caution. ^a
Neurotoxic drugs	↑ risk of neuropathy	Use with caution. ^b
Antacids containing magnesium or aluminum	↑ side effects associated with antacid components	Use caution with VIDEX Chewable/Dispersible Buffered Tablets and Pediatric Powder for Oral Solution.
Ribavirin	↑ risk of toxicity	Ribavirin has been shown <i>in vitro</i> to increase intracellular triphosphate levels of didanosine. Coadministration is not recommended (see below).
<i>Use with Caution, Plasma Concentrations May Be Decreased by Coadministration with VIDEX</i>		
Drug Class	Effect	Clinical Comment
Azole antifungals	↓ ketoconazole or itraconazole concentration	Administer drugs such as ketoconazole or itraconazole at least 2 hours before VIDEX.
Quinolone antibiotics (see also ciprofloxacin in Table 7)	↓ quinolone concentration	Consult package insert of the quinolone.
Tetracycline antibiotics	↓ antibiotic concentration	Consult package insert of the tetracycline.
↑ indicates increase.		
↓ indicates decrease.		
^a Only if other drugs are not available and if clearly indicated. If treatment with life-sustaining drugs that cause pancreatic toxicity is required, suspension of VIDEX is recommended (see WARNINGS: Pancreatitis).		
^b See PRECAUTIONS: Peripheral Neuropathy .		

Nucleoside/nucleotide analogues

Tenofovir disoproxil fumarate. Exposure to didanosine is increased when coadministered with tenofovir (see Table 3). **Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy. Coadministration of tenofovir with VIDEX**

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response. VIDEX should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop (see WARNINGS). A dose reduction of VIDEX to 250 mg (adults weighing ≥ 60 kg with creatinine clearance ≥ 60 mL/min) or 200 mg (adults weighing < 60 kg with creatinine clearance ≥ 60 mL/min) once daily is recommended. VIDEX and tenofovir may be taken together in the fasted state. Alternatively, if tenofovir is taken with food, VIDEX should be taken on an empty stomach, at least 30 minutes before food or 2 hours after food (see DOSAGE AND ADMINISTRATION). (The dosing recommendation for coadministration of VIDEX EC and tenofovir disoproxil fumarate with respect to meal consumption differs from that of VIDEX. See the complete prescribing information for VIDEX EC.)

Ribavirin. Exposure to the active metabolite of didanosine (dideoxyadenosine 5'-triphosphate) is increased when didanosine is coadministered with ribavirin (see Table 8). Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. Coadministration of didanosine and ribavirin is not recommended.

Carcinogenesis and Mutagenesis

Lifetime carcinogenicity studies were conducted in mice and rats for 22 and 24 months, respectively. In the mouse study, initial doses of 120, 800, and 1200 mg/kg/day for each sex were lowered after 8 months to 120, 210, and 210 mg/kg/day for females and 120, 300, and 600 mg/kg/day for males. The two higher doses exceeded the maximally tolerated dose in females and the high dose exceeded the maximally tolerated dose in males. The low dose in females represented 0.68-fold maximum human exposure and the intermediate dose in males represented 1.7-fold maximum human exposure based on relative AUC comparisons. In the rat study, initial doses were 100, 250, and 1000 mg/kg/day, and the high dose was lowered to 500 mg/kg/day after 18 months. The upper dose in male and female rats represented 3-fold maximum human exposure.

Didanosine induced no significant increase in neoplastic lesions in mice or rats at maximally tolerated doses.

Didanosine was positive in the following genetic toxicology assays: 1) the *Escherichia coli* tester strain WP2 uvrA bacterial mutagenicity assay; 2) the

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

L5178Y/TK+/-mouse lymphoma mammalian cell gene mutation assay; 3) the *in vitro* chromosomal aberrations assay in cultured human peripheral lymphocytes; 4) the *in vitro* chromosomal aberrations assay in Chinese Hamster Lung cells; and 5) the BALB/c 3T3 *in vitro* transformation assay. No evidence of mutagenicity was observed in an Ames *Salmonella* bacterial mutagenicity assay or in rat and mouse *in vivo* micronucleus assays.

Pregnancy, Reproduction, and Fertility

Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 12 and 14.2 times the estimated human exposure (based upon plasma levels), respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to didanosine. At approximately 12 times the estimated human exposure, didanosine was slightly toxic to female rats and their pups during mid and late lactation. These rats showed reduced food intake and body weight gains but the physical and functional development of the offspring was not impaired and there were no major changes in the F2 generation. A study in rats showed that didanosine and/or its metabolites are transferred to the fetus through the placenta. Animal reproduction studies are not always predictive of human response.

There are no adequate and well-controlled studies of didanosine in pregnant women. Didanosine should be used during pregnancy only if the potential benefit justifies the potential risk.

Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. It is unclear if pregnancy augments the risk of lactic acidosis/hepatic steatosis syndrome reported in nonpregnant individuals receiving nucleoside analogues (see **WARNINGS: Lactic Acidosis/Severe Hepatomegaly with Steatosis**). **The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk.** Health care providers caring for HIV-infected pregnant women receiving didanosine should be alert for early diagnosis of lactic acidosis/hepatic steatosis syndrome.

Antiretroviral Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women exposed to didanosine and other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Nursing Mothers

The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV. A study in rats showed that following oral administration, didanosine and/or its metabolites were excreted into the milk of lactating rats. It is not known if didanosine is excreted in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, **mothers should be instructed not to breast-feed if they are receiving VIDEX.**

Pediatric Use

Use of VIDEX in pediatric patients from 2 weeks of age through adolescence is supported by evidence from adequate and well-controlled studies of VIDEX in adults and pediatric patients (see **INDICATIONS AND USAGE: Clinical Studies, CLINICAL PHARMACOLOGY, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION**).

Dosing recommendations for VIDEX in patients less than 2 weeks of age cannot be made because the pharmacokinetics of didanosine in these children are too variable to determine an appropriate dose.

Geriatric Use

In an Expanded Access Program for patients with advanced HIV infection, patients aged 65 years and older had a higher frequency of pancreatitis (10%) than younger patients (5%) (see **WARNINGS**). Clinical studies of didanosine did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently than younger subjects. Didanosine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. In addition, renal function should be monitored and dosage adjustments should be made accordingly (see **DOSAGE AND ADMINISTRATION: Dose Adjustment**).

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

ADVERSE REACTIONS

A SERIOUS TOXICITY OF VIDEX (didanosine) IS PANCREATITIS, WHICH MAY BE FATAL (see **WARNINGS**). OTHER IMPORTANT TOXICITIES INCLUDE LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS; RETINAL CHANGES AND OPTIC NEURITIS; AND PERIPHERAL NEUROPATHY (see **WARNINGS** and **PRECAUTIONS**).

When VIDEX is used in combination with other agents with similar toxicities, the incidence of these toxicities may be higher than when VIDEX is used alone. Thus, patients treated with VIDEX in combination with stavudine, with or without hydroxyurea, may be at increased risk for pancreatitis and hepatotoxicity, which may be fatal, and severe peripheral neuropathy (see **WARNINGS** and **PRECAUTIONS**).

Adults: Selected clinical adverse events that occurred in adult patients in clinical studies with VIDEX are provided in Tables 9 and 10.

Table 9: Selected Clinical Adverse Events from Monotherapy Studies

Adverse Events	Percent of Patients			
	ACTG 116A		ACTG 116B/117	
	VIDEX n=197	zidovudine n=212	VIDEX n=298	zidovudine n=304
Diarrhea	19	15	28	21
Peripheral Neurologic Symptoms/Neuropathy	17	14	20	12
Rash/Pruritus	7	8	9	5
Abdominal Pain	13	8	7	8
Pancreatitis	7	3	6	2

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 10: Selected Clinical Adverse Events from Combination Studies

Adverse Events	Percent of Patients ^a			
	AI454-148 ^b		START 2 ^b	
	VIDEX + stavudine + nelfinavir n=482	zidovudine + lamivudine + nelfinavir n=248	VIDEX + stavudine + indinavir n=102	zidovudine + lamivudine + indinavir n=103
Diarrhea	70	60	45	39
Nausea	28	40	53	67
Headache	21	30	46	37
Peripheral Neurologic Symptoms/Neuropathy	26	6	21	10
Rash	13	16	30	18
Vomiting	12	14	30	35
Pancreatitis (see below)	1	*	<1	*

^a Percentages based on treated subjects.
^b Median duration of treatment 48 weeks.
 * This event was not observed in this study arm.

Pancreatitis resulting in death was observed in one patient who received VIDEX (didanosine) plus stavudine plus nelfinavir in Study AI454-148 and in one patient who received VIDEX plus stavudine plus indinavir in the START 2 study. In addition, pancreatitis resulting in death was observed in 2 of 68 patients who received VIDEX plus stavudine plus indinavir plus hydroxyurea in an ACTG clinical trial (see WARNINGS).

The frequency of pancreatitis is dose related. In phase 3 studies, incidence ranged from 1% to 10% with doses higher than are currently recommended and from 1% to 7% with recommended dose.

Selected laboratory abnormalities in clinical studies with VIDEX are shown in Tables 11-13.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 11: Selected Laboratory Abnormalities from Monotherapy Studies

Parameter	Percent of Patients			
	ACTG 116A		ACTG 116B/117	
	VIDEX n=197	zidovudine n=212	VIDEX n=298	zidovudine n=304
SGOT (AST) (>5 x ULN)	9	4	7	6
SGPT (ALT) (>5 x ULN)	9	6	6	6
Alkaline phosphatase (>5 x ULN)	4	1	1	1
Amylase (\geq 1.4 x ULN)	17	12	15	5
Uric acid (>12 mg/dL)	3	1	2	1

ULN = upper limit of normal.

Table 12: Selected Laboratory Abnormalities from Combination Studies (Grades 3-4)

Parameter	Percent of Patients ^a			
	AI454-148 ^b		START 2 ^b	
	VIDEX + stavudine + nelfinavir n=482	zidovudine + lamivudine + nelfinavir n=248	VIDEX + stavudine + indinavir n=102	zidovudine + lamivudine + indinavir n=103
Bilirubin (>2.6 x ULN)	<1	<1	16	8
SGOT (AST) (>5 x ULN)	3	2	7	7
SGPT (ALT) (>5 x ULN)	3	3	8	5
GGT (>5 x ULN)	NC	NC	5	2
Lipase (>2 x ULN)	7	2	5	5
Amylase (>2 x ULN)	NC	NC	8	2

ULN = upper limit of normal.

NC = Not Collected.

^a Percentages based on treated subjects.

^b Median duration of treatment 48 weeks.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 13: Selected Laboratory Abnormalities from Combination Studies (All Grades)

Parameter	Percent of Patients ^a			
	AI454-148 ^b		START 2 ^b	
	VIDEX + stavudine + nelfinavir n=482	zidovudine + lamivudine + nelfinavir n=248	VIDEX + stavudine + indinavir n=102	zidovudine + lamivudine + indinavir n=103
Bilirubin	7	3	68	55
SGOT (AST)	42	23	53	20
SGPT (ALT)	37	24	50	18
GGT	NC	NC	28	12
Lipase	17	11	26	19
Amylase	NC	NC	31	17

NC = Not Collected.

^a Percentages based on treated subjects.

^b Median duration of treatment 48 weeks.

Observed during Clinical Practice: The following events have been identified during postapproval use of VIDEX (didanosine). Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to their seriousness, frequency of reporting, causal connection to VIDEX, or a combination of these factors.

Body as a Whole – alopecia, anaphylactoid reaction, asthenia, chills/fever, pain, and redistribution/accumulation of body fat (see **PRECAUTIONS: Fat Redistribution**).

Digestive Disorders – anorexia, dyspepsia, and flatulence.

Exocrine Gland Disorders – pancreatitis (including fatal cases) (see **WARNINGS**), sialoadenitis, parotid gland enlargement, dry mouth, and dry eyes.

Hematologic Disorders – anemia, leukopenia, and thrombocytopenia.

Liver – symptomatic hyperlactatemia/lactic acidosis and hepatic steatosis (see **WARNINGS**); hepatitis and liver failure.

Metabolic Disorders – diabetes mellitus, hypoglycemia, and hyperglycemia.

Musculoskeletal Disorders – myalgia (with or without increases in creatine kinase), rhabdomyolysis including acute renal failure and hemodialysis, arthralgia, and myopathy.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Ophthalmologic Disorders – Retinal depigmentation and optic neuritis (see **WARNINGS**).

Pediatric Patients: In clinical trials, 743 pediatric patients between 2 weeks and 18 years of age have been treated with VIDEX. Adverse events and laboratory abnormalities reported to occur in these patients were generally consistent with the safety profile of didanosine in adults.

In pediatric phase 1 studies, pancreatitis occurred in 2 of 60 (3%) patients treated at entry doses below 300 mg/m²/day and in 5 of 38 (13%) patients treated at higher doses. In study ACTG 152, pancreatitis occurred in none of the 281 pediatric patients who received didanosine 120 mg/m² q12h and in <1% of the 274 pediatric patients who received didanosine 90 mg/m² q12h in combination with zidovudine (see **INDICATIONS AND USAGE: Clinical Studies**).

Retinal changes and optic neuritis have been reported in pediatric patients.

OVERDOSAGE

There is no known antidote for VIDEX (didanosine) overdose. In phase 1 studies, in which VIDEX was initially administered at doses ten times the currently recommended dose, toxicities included: pancreatitis, peripheral neuropathy, diarrhea, hyperuricemia, and hepatic dysfunction. Didanosine is not dialyzable by peritoneal dialysis, although there is some clearance by hemodialysis (see **CLINICAL PHARMACOLOGY: Pharmacokinetics**).

DOSAGE AND ADMINISTRATION

Dosage

All VIDEX formulations should be administered on an empty stomach, at least 30 minutes before or 2 hours after eating. For either a once-daily or twice-daily regimen, patients must take at least two of the appropriate strength tablets at each dose to provide adequate buffering and prevent gastric acid degradation of didanosine. Because of the need for adequate buffering, the 200-mg strength tablet should only be used as a component of a once-daily regimen. To reduce the risk of gastrointestinal side effects, patients should take no more than four tablets at each dose.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Adults: The preferred dosing frequency of VIDEX is twice daily because there is more evidence to support the effectiveness of this dosing regimen. Once-daily dosing should be considered only for adult patients whose management requires once-daily dosing of VIDEX (see **INDICATIONS AND USAGE: Clinical Studies**). The daily dose in adult patients is dependent on weight as outlined in Table 14.

Table 14: Adult Dosing^a

	Recommended VIDEX Dose by Patient Weight	
	≥60 kg	<60 kg
Preferred dosing	200 mg twice daily	125 mg twice daily
Dosing for patients whose management requires once-daily frequency	400 mg once daily	250 mg once daily

^aThe 200-mg strength tablet should only be used as a component of a once-daily regimen.

Pediatric Patients: The recommended dose of VIDEX (didanosine) in pediatric patients between 2 weeks and 8 months of age is 100 mg/m² twice daily, and the recommended VIDEX dose for pediatric patients older than 8 months is 120 mg/m² twice daily.

Dosing recommendations for VIDEX in patients less than 2 weeks of age cannot be made because the pharmacokinetics of didanosine in these children are too variable to determine an appropriate dose. There are no data on once-daily dosing of VIDEX in pediatric patients.

Dose Adjustment

Clinical and laboratory signs suggestive of pancreatitis should prompt dose suspension and careful evaluation of the possibility of pancreatitis. VIDEX use should be discontinued in patients with confirmed pancreatitis (see WARNINGS and PRECAUTIONS: Drug Interactions).

Patients with symptoms of peripheral neuropathy may tolerate a reduced dose of VIDEX after resolution of the symptoms of peripheral neuropathy upon drug discontinuation. If neuropathy recurs after resumption of VIDEX, permanent discontinuation of VIDEX should be considered.

Concomitant Therapy: *Tenofovir disoproxil fumarate*. A dose reduction of VIDEX to 250 mg (adults weighing ≥60 kg with creatinine clearance ≥60 mL/min) or 200

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

mg (adults weighing <60 kg with creatinine clearance ≥ 60 mL/min) once daily is recommended. VIDEX and tenofovir may be taken together in the fasted state. Alternatively, if tenofovir is taken with food, VIDEX should be taken on an empty stomach (at least 30 minutes before food or 2 hours after food). **The appropriate dose of VIDEX coadministered with tenofovir in patients with creatinine clearance <60 mL/min has not been established.** [See **CLINICAL PHARMACOLOGY: Drug Interactions** and **PRECAUTIONS: Drug Interactions**; see the complete prescribing information for VIDEX EC (enteric-coated formulation of didanosine) for results of drug interaction studies of tenofovir with reduced doses of the enteric-coated formulation of didanosine.]

Renal Impairment: In adult patients with impaired renal function, the dose of VIDEX should be adjusted to compensate for the slower rate of elimination. The recommended doses and dosing intervals of VIDEX in adult patients with renal insufficiency are presented in Table 15.

Table 15: Recommended Dosage of VIDEX in Renal Impairment^a

Creatinine Clearance (mL/min)	Recommended VIDEX Dose by Patient Weight	
	≥ 60 kg	<60 kg
≥ 60	200 mg twice daily ^b	125 twice daily ^b
30-59	200 mg once daily or 100 mg twice daily	150 mg once daily or 75 mg twice daily
10-29	150 mg once daily	100 mg once daily
<10	100 mg once daily	75 mg once daily

^a Two VIDEX Chewable/Dispersible Buffered tablets must be taken with each dose; different strengths of tablets may be combined to yield the recommended dose.

^b 400 mg once daily (≥ 60 kg) or 250 mg once daily (<60 kg) for patients whose management requires once-daily frequency of administration.

Urinary excretion is also a major route of elimination of didanosine in pediatric patients; therefore, the clearance of didanosine may be altered in children with renal impairment. Although there are insufficient data to recommend a specific dose adjustment of VIDEX in this patient population, a reduction in the dose and/or an increase in the interval between doses should be considered.

Patients Requiring Continuous Ambulatory Peritoneal Dialysis (CAPD) or Hemodialysis: For patients requiring CAPD or hemodialysis, follow dosing

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

recommendations for patients with creatinine clearance less than 10 mL/min, shown in Table 15. It is not necessary to administer a supplemental dose of VIDEX following hemodialysis.

Hepatic Impairment and Toxicity: See WARNINGS.

Method of Preparation

VIDEX Chewable/Dispersible Buffered Tablets

Adult Dosing: To provide adequate buffering, at least two of the appropriate strength tablets, but no more than four tablets, should be thoroughly chewed or dispersed in at least 1 ounce of water prior to consumption (see **PRECAUTIONS: Information for Patients**). To disperse tablets, add 2 tablets to at least 1 ounce of drinking water. Stir until a uniform dispersion forms, and drink the entire dispersion immediately. If additional flavoring is desired, the dispersion may be diluted with one ounce of clear apple juice. Stir the further diluted dispersion just prior to consumption. The dispersion with clear apple juice is stable at room temperature, 62° to 73°F (17° to 23°C), for up to one hour.

VIDEX Pediatric Powder for Oral Solution

Prior to dispensing, the pharmacist must constitute dry powder with Purified Water, USP, to an initial concentration of 20 mg/mL and immediately mix the resulting solution with antacid to a final concentration of 10 mg/mL as follows:

20 mg/mL Initial Solution: Constitute the product to 20 mg/mL by adding 100 mL or 200 mL of Purified Water, USP, to the 2 g or 4 g of VIDEX powder, respectively, in the product bottle.

10 mg/mL Final Admixture: 1. Immediately mix one part of the 20 mg/mL initial solution with one part of Maximum Strength Mylanta[®] Liquid for a final dispensing concentration of 10 mg VIDEX per mL. For patient home use, the admixture should be dispensed in appropriately sized, flint-glass or plastic (HDPE, PET, or PETG) bottles with child-resistant closures. This admixture is stable for 30 days under refrigeration, 36° to 46° F (2° to 8° C).

2. Instruct the patient to shake the admixture thoroughly prior to use and to store the tightly closed container in the refrigerator, 36° to 46° F (2° to 8° C), up to 30 days.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

HOW SUPPLIED

VIDEX[®] (didanosine) Chewable/Dispersible Buffered Tablets are round, off white to light orange/yellow with a mottled appearance, orange-flavored, tablets embossed with "VIDEX" on one side and the product strength on the other. The tablets are available in the following strengths of VIDEX: 25, 50, 100, 150, and 200 mg. Sixty tablets are packaged in bottles with child-resistant closures.

The tablets should be stored in tightly closed bottles at 59° to 86° F (15° to 30° C). If dispersed in water, the dose may be held for up to 1 hour at ambient temperature.

VIDEX (didanosine) Pediatric Powder for Oral Solution is supplied in 4- and 8-ounce glass bottles containing 2 g or 4 g of VIDEX, respectively.

The bottles of powder should be stored at 59° to 86° F (15° to 30° C). The VIDEX admixture may be stored up to 30 days in a refrigerator, 36° to 46° F (2° to 8°C). Discard any unused portion after 30 days.

The NDC numbers for the previously described VIDEX products are:

Table 16

NDC NO.	Packaging Information	Product Strength
VIDEX[®] Chewable/Dispersible Buffered Tablets		
0087-6650-01	60 tablets/bottle	25 mg/tablet
0087-6651-01	60 tablets/bottle	50 mg/tablet
0087-6652-01	60 tablets/bottle	100 mg/tablet
0087-6653-01	60 tablets/bottle	150 mg/tablet
0087-6665-15	60 tablets/bottle	200 mg/tablet
VIDEX[®] Pediatric Powder for Oral Solution		
0087-6632-41	One bottle per carton	2 g/bottle
0087-6633-41	One bottle per carton	4 g/bottle

US Patent Nos.: 4,861,759, 5,254,539, 5,616,566 and 5,880,106.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

HANDLING AND DISPOSAL

Spill, Leak, and Disposal Procedure

Avoid generating dust during clean-up of powdered products; use wet mop or damp sponge. Clean surface with soap and water as necessary. Containerize larger spills.

There is no single preferred method of disposal of containerized waste. Disposal options include incineration, landfill, or sewer as dictated by specific circumstances and relevant national, state, and local regulations.

Mylanta[®] is a registered trademark of Johnson & Johnson-Merck Consumer Pharmaceuticals Company.

Bristol-Myers Squibb Virology
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA

1196181A2

Revised July 2006

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Patient Information

Rx only

VIDEX[®]

(generic name = **didanosine** also known as **ddl**)

VIDEX[®] (didanosine) Chewable/Dispersible Buffered Tablets

VIDEX[®] (didanosine) Pediatric Powder for Oral Solution

What is VIDEX?

VIDEX (pronounced VY dex) is a prescription medicine used in combination with other drugs to treat children and adults who are infected with HIV (the human immunodeficiency virus, the virus that causes AIDS). VIDEX belongs to a class of drugs called nucleoside analogues. By reducing the growth of HIV, VIDEX helps your body maintain its supply of CD4 cells, which are important for fighting HIV and other infections.

VIDEX will not cure your HIV infection. At present there is no cure for HIV infection. Even while taking VIDEX, you may continue to have HIV-related illnesses, including infections with other disease-producing organisms. Continue to see your doctor regularly and report any medical problems that occur.

VIDEX does not prevent a patient infected with HIV from passing the virus to other people. To protect others, you must continue to practice safe sex and take precautions to prevent others from coming in contact with your blood and other body fluids.

There is limited information on the effects of long-term use of VIDEX.

Who should not take VIDEX?

Do not take VIDEX if you are allergic to any of its ingredients, including its active ingredient, didanosine and the inactive ingredients. (See **Inactive Ingredients** at the end of this leaflet.) Tell your doctor if you think you have had an allergic reaction to any of these ingredients.

How should I take VIDEX? How should I store it?

Your doctor will determine your dose based on your body weight, kidney and liver function, other medicines you are taking, and any side effects that you may have had with VIDEX or other medicines. Take VIDEX **on an empty stomach - that means at least 30 minutes before or 2 hours after eating. Do not take VIDEX with food.** Try not to miss a dose, but if you do, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule.

Chewable/Dispersible Tablets: Each VIDEX tablet contains antacid. Each time you take VIDEX, you must take at least two, but not more than four, tablets. This is because VIDEX tablets contain an antacid to reduce the amount of acid in your stomach. If you have too much acid, the medicine will break down. However, too much antacid may cause stomach problems.

—**DO NOT** swallow VIDEX tablets whole. Chew the tablets well or mix them in water. Many patients drop the tablets in at least one ounce of water and stir well before swallowing. If you choose to mix the tablets in water, you may add one ounce (2 tablespoons) of clear apple juice to the mixture for flavor (do not use any other kind of juice).

—Store tablets in a tightly closed container at room temperature away from heat and out of the reach of children and pets. Do NOT store the tablets in a damp place such as a bathroom medicine cabinet or near the kitchen sink.

Pediatric Oral Solution: Your pharmacist will prepare the oral solution. Shake the solution well before each use. Store in the refrigerator. Throw away any unused portion after 30 days.

If you have kidney disease: If your kidneys are not working properly, your doctor will need to do regular tests to check how they are working while you take VIDEX. Your doctor may also lower your dosage of VIDEX.

What should I do if someone takes an overdose of VIDEX?

If someone may have taken an overdose of VIDEX, get medical help right away. Contact their doctor or a poison control center.

What should I avoid while taking VIDEX?

Alcohol. Do not drink alcohol while taking VIDEX since alcohol may increase your risk of pancreatitis (pain and inflammation of the pancreas) or liver damage.

Other medicines. Other medicines, including those you can buy without a prescription, may interfere with the actions of VIDEX or may increase the possibility or severity of side effects. **Do not take any medicine, vitamin supplement, or other health preparation without first checking with your doctor.**

Antacids. Since VIDEX contains some of the same ingredients found in antacids, any side effects related to VIDEX's ingredients may get worse if you also take an antacid.

Medicines at the same time you take your VIDEX dose. Some medicines should not be taken at the same time of day that you take VIDEX. Check with your doctor.

Pregnancy. It is not known if VIDEX can harm a human fetus. Also, pregnant women have experienced serious side effects when taking VIDEX in combination with ZERIT (stavudine), also known as d4T, and other HIV medicines. VIDEX should be used during pregnancy only after discussion with your doctor. **Tell your doctor if you become pregnant or plan to become pregnant while taking VIDEX.**

Nursing. Studies have shown VIDEX is in the breast milk of animals getting the drug. It may also be in human breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers **not** breast-feed. This should reduce the risk of passing HIV infection to their babies and the potential for serious adverse reactions in nursing infants. Therefore, do not nurse a baby while taking VIDEX.

What are the possible side effects of VIDEX?

Pancreatitis. Pancreatitis is a dangerous inflammation of the pancreas that may cause death. ***Tell your doctor right away if you or a child taking VIDEX develops stomach pain, nausea, or vomiting. These can be signs of pancreatitis.*** Before starting VIDEX therapy, let your doctor know if you or a child for whom it has been prescribed has ever had pancreatitis. This condition is more likely to happen in people who have had it before. It is

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

also more likely in people with advanced HIV disease. However, it can occur at any stage of HIV disease. It may be more common in patients with kidney problems, those who drink alcohol, and those who are also treated with stavudine or hydroxyurea. If you get pancreatitis, your doctor will tell you to stop taking VIDEX.

Lactic acidosis, severe liver enlargement, and liver failure, including deaths, have been reported among patients taking VIDEX (including pregnant women). Symptoms that may indicate a liver problem are:

- feeling very weak, tired, or uncomfortable,
- unusual or unexpected stomach discomfort,
- feeling cold,
- feeling dizzy or lightheaded,
- suddenly developing a slow or irregular heartbeat.

Lactic acidosis is a medical emergency that must be treated in a hospital.

If you notice any of these symptoms or if your medical condition changes, stop taking VIDEX and **call your doctor right away**. Women, overweight patients, and those who have been treated for a long time with other medicines used to treat HIV infection are more likely to develop lactic acidosis. Your doctor should check your liver function periodically while you are taking VIDEX. You should be especially careful if you have a history of heavy alcohol use or a liver problem.

Vision changes. VIDEX may affect the nerves in your eyes. Because of this, you should have regular eye examinations. You should also report any changes in vision to your doctor right away. This includes, for example, seeing colors abnormally or blurred vision.

Peripheral neuropathy. This is a problem with the nerves in your hands or feet. The nerve problem may be serious. ***Tell your doctor right away if you or a child taking VIDEX has continuing numbness, tingling, or pain in the feet or hands.*** A child may not recognize these symptoms or know to tell you that his or her feet or hands are numb, burning, tingling, or painful. Ask your child's doctor how to find out if your child is developing peripheral neuropathy.

Before starting VIDEX therapy, let your doctor know if you or a child for whom it has been prescribed has ever had peripheral neuropathy. This condition is more likely to happen in people who have had it before. It is also more likely in patients taking medicines that affect the

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

nerves and in people with advanced HIV disease. However, it can occur at any stage of HIV disease. If you get peripheral neuropathy, your doctor will tell you to stop taking VIDEX. After stopping VIDEX, the symptoms may get worse for a short time and then get better. Once symptoms of peripheral neuropathy go away completely, you and your doctor should decide if starting VIDEX is right for you. If so, you might be started at a lower dose.

Special note about other medicines. If you take VIDEX along with other medicines with similar side effects, you may increase the chance of having these side effects. For example, using VIDEX in combination with other medicines that may cause pancreatitis, peripheral neuropathy, or liver problems (including stavudine and hydroxyurea) may increase your chance of having these side effects.

Other side effects: The most common side effects in adults taking VIDEX are diarrhea, neuropathy (nerve disorders), chills or fever, rash, abdominal pain, weakness, headache, and nausea and vomiting. Children may have similar side effects as adults.

Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck (“buffalo hump”), breast, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known at this time.

What else should I know about VIDEX?

If you have phenylketonuria: Each Chewable/Dispersible Tablet contains 36.5 mg of phenylalanine.

Inactive Ingredients:

Chewable/Dispersible Tablets: calcium carbonate, magnesium hydroxide, aspartame, sorbitol, mandarin orange flavor, polyplasdone, microcrystalline cellulose, and magnesium stearate.

Pediatric Oral Solution: Maximum Strength Mylanta[®] Liquid.

This medicine was prescribed for your particular condition. Do not use VIDEX for another condition or give it to others. Keep VIDEX and all medicines out of the reach of children. Throw away VIDEX when it is outdated or no longer needed by flushing it down the toilet or pouring it down the sink.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

This summary does not include everything there is to know about VIDEX. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. If you have questions or concerns, or want more information about VIDEX, your physician and pharmacist have the complete prescribing information upon which this leaflet is based. You may want to read it and discuss it with your doctor or other healthcare professional. Remember, no written summary can replace careful discussion with your doctor.

Mylanta[®] is a registered trademark of Johnson & Johnson-Merck Consumer Pharmaceuticals Company.

Bristol-Myers Squibb Virology
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA

This Patient Information Leaflet has been approved by the U.S. Food and Drug Administration.

1196181A2

Revised July 2006
Based on package insert dated July 2006

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Rx only

VIDEX[®] EC (didanosine)

VIDEX[®] EC (didanosine) Delayed-Release Capsules
Enteric-Coated Beadlets

(Patient Information Leaflet Included)

WARNING

FATAL AND NONFATAL PANCREATITIS HAVE OCCURRED DURING THERAPY WITH DIDANOSINE USED ALONE OR IN COMBINATION REGIMENS IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, REGARDLESS OF DEGREE OF IMMUNOSUPPRESSION. VIDEX EC SHOULD BE SUSPENDED IN PATIENTS WITH SUSPECTED PANCREATITIS AND DISCONTINUED IN PATIENTS WITH CONFIRMED PANCREATITIS (SEE WARNINGS).

LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES ALONE OR IN COMBINATION, INCLUDING DIDANOSINE AND OTHER ANTIRETROVIRALS. FATAL LACTIC ACIDOSIS HAS BEEN REPORTED IN PREGNANT WOMEN WHO RECEIVED THE COMBINATION OF DIDANOSINE AND STAVUDINE WITH OTHER ANTIRETROVIRAL AGENTS. THE COMBINATION OF DIDANOSINE AND STAVUDINE SHOULD BE USED WITH CAUTION DURING PREGNANCY AND IS RECOMMENDED ONLY IF THE POTENTIAL BENEFIT CLEARLY OUTWEIGHS THE POTENTIAL RISK (SEE WARNINGS AND PRECAUTIONS: PREGNANCY).


NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

DESCRIPTION

VIDEX[®] EC is the brand name for an enteric-coated formulation of didanosine (ddI), a synthetic purine nucleoside analogue active against the Human Immunodeficiency Virus (HIV). VIDEX EC (didanosine) Delayed-Release Capsules, containing enteric-coated beadlets, are available for oral administration in strengths of 125, 200, 250, and 400 mg of didanosine. The inactive ingredients in the beadlets include carboxymethylcellulose sodium 12, diethyl phthalate, methacrylic acid copolymer, sodium hydroxide, sodium starch glycolate, and talc. The capsule shells contain colloidal silicon dioxide, gelatin, sodium lauryl sulfate, and titanium dioxide. The capsules are imprinted with edible inks.

Didanosine is also available as buffered formulations. Please consult the prescribing information for VIDEX (didanosine) Chewable/Dispersible Buffered Tablets and Pediatric Powder for Oral Solution for additional information.

The chemical name for didanosine is 2',3'-dideoxyinosine. The structural formula is:



Didanosine is a white crystalline powder with the molecular formula $C_{10}H_{12}N_4O_3$ and a molecular weight of 236.2. The aqueous solubility of didanosine at 25° C and pH of approximately 6 is 27.3 mg/mL. Didanosine is unstable in acidic solutions. For example, at pH <3 and 37° C, 10% of didanosine decomposes to hypoxanthine in less than 2 minutes. In VIDEX EC, an enteric coating is used to protect didanosine from degradation by stomach acid.

MICROBIOLOGY

Mechanism of Action

Didanosine is a synthetic nucleoside analogue of the naturally occurring nucleoside deoxyadenosine in which the 3'-hydroxyl group is replaced by hydrogen. Intracellularly, didanosine is converted by cellular enzymes to the active metabolite, dideoxyadenosine 5'-triphosphate. Dideoxyadenosine 5'-triphosphate inhibits the activity of HIV-1 reverse transcriptase both by competing with the natural substrate, deoxyadenosine 5'-triphosphate, and by its incorporation into viral DNA causing termination of viral DNA chain elongation.

***In Vitro* HIV Susceptibility**

The *in vitro* anti-HIV-1 activity of didanosine was evaluated in a variety of HIV-1 infected lymphoblastic cell lines and monocyte/macrophage cell cultures. The concentration of drug necessary to inhibit viral replication by 50% (IC₅₀) ranged from 2.5 to 10 μ M (1 μ M = 0.24 μ g/mL) in lymphoblastic cell lines and 0.01 to 0.1 μ M in monocyte/macrophage cell cultures. The relationship between *in vitro* susceptibility of HIV to didanosine and the inhibition of HIV replication in humans has not been established.

Drug Resistance

HIV-1 isolates with reduced sensitivity to didanosine have been selected *in vitro* and were also obtained from patients treated with didanosine. Genetic analysis of isolates from didanosine-treated patients showed mutations in the reverse transcriptase gene that resulted in the amino acid substitutions K65R, L74V, and M184V. The L74V mutation was most frequently observed in clinical isolates. Phenotypic analysis of HIV-1 isolates from 60 patients (some with prior zidovudine treatment) receiving 6 to 24 months of didanosine monotherapy showed that isolates from 10 of 60 patients exhibited an average of a 10-fold decrease in susceptibility to didanosine *in vitro* compared to baseline isolates. Clinical isolates that exhibited a decrease in didanosine susceptibility harbored one or more didanosine-associated mutations. The clinical relevance of genotypic and phenotypic changes associated with didanosine therapy has not been established.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Cross-resistance

HIV-1 isolates from 2 of 39 patients receiving combination therapy for up to 2 years with zidovudine and didanosine exhibited decreased susceptibility to zidovudine, didanosine, zalcitabine, stavudine, and lamivudine *in vitro*. These isolates harbored five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the reverse transcriptase gene. The clinical relevance of these observations has not been established.

CLINICAL PHARMACOLOGY

Animal Toxicology

Evidence of a dose-limiting skeletal muscle toxicity has been observed in mice and rats (but not in dogs) following long-term (greater than 90 days) dosing with didanosine at doses that were approximately 1.2 to 12 times the estimated human exposure. The relationship of this finding to the potential of didanosine to cause myopathy in humans is unclear. However, human myopathy has been associated with administration of didanosine and other nucleoside analogues.

Pharmacokinetics

The pharmacokinetic parameters of didanosine are summarized in Table 1. Didanosine is rapidly absorbed, with peak plasma concentrations generally observed from 0.25 to 1.50 hours following oral dosing with a buffered formulation. Increases in plasma didanosine concentrations were dose proportional over the range of 50 to 400 mg. Steady-state pharmacokinetic parameters did not differ significantly from values obtained after a single dose. Binding of didanosine to plasma proteins *in vitro* was low (<5%). Based on data from *in vitro* and animal studies, it is presumed that the metabolism of didanosine in man occurs by the same pathways responsible for the elimination of endogenous purines.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 1: Pharmacokinetic Parameters for Didanosine in Adults		
Parameter	Mean ± SD	n
Oral bioavailability	42 ± 12%	6
Apparent volume of distribution	1.08 ± 0.22 L/kg	6
CSF-plasma ratio ^b	21 ± 0.03%	5
Systemic clearance ^b	13.0 ± 1.6 mL/min/kg	6
Renal clearance ^a	5.5 ± 2.1 mL/min/kg	6
Elimination half-life ^a	1.5 ± 0.4 h	6
Urinary recovery of didanosine ^a	18 ± 8%	6
CSF = cerebrospinal fluid.		
^a following oral administration of a buffered formulation.		
^b following IV administration.		
^c mean ± SE.		

Comparison of Didanosine Formulations

In VIDEX EC, the active ingredient, didanosine, is protected against degradation by stomach acid by the use of an enteric coating on the beadlets in the capsule. The enteric coating dissolves when the beadlets empty into the small intestine, the site of drug absorption. With buffered formulations of didanosine, administration with antacid provides protection from degradation by stomach acid.

In healthy volunteers, as well as subjects infected with HIV, the area under the plasma concentration time curve (AUC) is equivalent for didanosine administered as the VIDEX EC formulation relative to a buffered tablet formulation. The peak plasma concentration (C_{MAX}) of didanosine, administered as VIDEX EC, is reduced approximately 40% relative to didanosine buffered tablets. The time to the peak concentration (T_{MAX}) increases from approximately 0.67 hours for didanosine buffered tablets to 2.0 hours for VIDEX EC.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Effect of Food on Absorption of Didanosine

In the presence of food, the C_{MAX} and AUC for VIDEX EC were reduced by approximately 46% and 19%, respectively, compared to the fasting state. VIDEX EC should be taken on an empty stomach.

Special Populations

Renal Insufficiency

It is recommended that the VIDEX EC (didanosine) dose be modified in patients with reduced creatinine clearance and in patients receiving maintenance hemodialysis (see **DOSAGE AND ADMINISTRATION**). Data from two studies using a buffered formulation of didanosine indicated that the apparent oral clearance of didanosine decreased and the terminal elimination half-life increased as creatinine clearance decreased (see Table 2). Following oral administration, didanosine was not detectable in peritoneal dialysate fluid (n=6); recovery in hemodialysate (n=5) ranged from 0.6% to 7.4% of the dose over a 3-4 hour dialysis period. The absolute bioavailability of didanosine was not affected in patients requiring dialysis.

Parameter	Creatinine Clearance (mL/min)				Dialysis Patients (n=11)
	≥ 90 (n=12)	60-90 (n=6)	30-59 (n=6)	10-29 (n=3)	
CL_{cr} (mL/min)	112 ± 22	68 ± 8	46 ± 8	13 ± 5	ND
CL/F (mL/min)	2164 ± 638	1566 ± 833	1023 ± 378	628 ± 104	543 ± 174
CL_R (mL/min)	458 ± 164	247 ± 153	100 ± 44	20 ± 8	<10
$T_{1/2}$ (h)	1.42 ± 0.33	1.59 ± 0.13	1.75 ± 0.43	2.0 ± 0.3	4.1 ± 1.2

ND = not determined due to anuria.
 CL_{cr} = creatinine clearance.
 CL/F = apparent oral clearance.
 CL_R = renal clearance.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Pediatric Patients

The pharmacokinetics of didanosine administered as VIDEX EC have not been studied in pediatric patients.

Geriatric Patients

Didanosine pharmacokinetics have not been studied in patients over 65 years of age (see **PRECAUTIONS: Geriatric Use**).

Gender

The effects of gender on didanosine pharmacokinetics have not been studied.

Drug Interactions (See also PRECAUTIONS: Drug Interactions.)

Ribavirin has been shown *in vitro* to increase intracellular triphosphate levels of didanosine, which could cause or worsen clinical toxicities (see **PRECAUTIONS: Drug Interactions**).

VIDEX EC

Tables 3 and 4 summarize the effects on AUC and C_{MAX} , with a 90% confidence interval (CI) when available, following coadministration of VIDEX EC with a variety of drugs. Clinical recommendations based on drug interaction studies for drugs in bold font are included in **PRECAUTIONS: Drug Interactions** and **DOSAGE AND ADMINISTRATION**.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 3: Results of Drug Interaction Studies with VIDEX EC: Effects of Coadministered Drug on Didanosine Plasma AUC and C_{MAX} Values^a

Drug	Didanosine Dosage	n	AUC of Didanosine (90% CI)	C _{MAX} of Didanosine (90% CI)
tenofovir, ^b 300 mg once daily with a light meal ^c	400 mg single dose fasting 2 h before tenofovir	26	↑ 48% (31, 67%)	↑ 48% (25, 76%)
tenofovir, ^b 300 mg once daily with a light meal ^c	400 mg single dose with tenofovir and a light meal	25	↑ 60% (44, 79%)	↑ 64% (41, 89%)
tenofovir, ^b 300 mg once daily with a light meal ^c	200 mg single dose with tenofovir and a light meal	33	↑ 16% (6, 27%) ^d	↓ 12% (-25, 3%) ^d
	250 mg single dose with tenofovir and a light meal	33	↔ (-13, 5%) ^e	↓ 20% (-32, -7%) ^e
	325 mg single dose with tenofovir and a light meal	33	↑ 13% (3, 24%) ^e	↓ 11% (-24, 4%) ^e

↑ indicates increase.
 ↓ indicates decrease.
 ↔ indicates no change, or mean increase or decrease of <10%.
^a All studies conducted in healthy volunteers ≥60 kg with creatinine clearance ≥60 mL/min.
^b tenofovir disoproxil fumarate.
^c 373 kcalories, 8.2 grams fat.
^d Compared with VIDEX EC 250 mg administered alone under fasting conditions.
^e Compared with VIDEX EC 400 mg administered alone under fasting conditions.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 4: Results of Drug Interaction Studies with VIDEX EC: Effects of Didanosine on Coadministered Drug Plasma AUC and C_{MAX} Values^a

Drug	Didanosine Dosage	n	AUC of Coadministered Drug	C _{MAX} of Coadministered Drug
ciprofloxacin, 750 mg single dose	400 mg single dose	16	↔	↔
indinavir, 800 mg single dose	400 mg single dose	23	↔	↔
ketoconazole, 200 mg single dose	400 mg single dose	21	↔	↔
tenofovir, ^b 300 mg once daily with a light meal ^c	400 mg single dose fasting 2 h before tenofovir	25	↔	↔
tenofovir, ^b 300 mg once daily with a light meal ^c	400 mg single dose with tenofovir and a light meal	25	↔	↔

↔ indicates no change, or mean increase or decrease of <10%.
^a All studies conducted in healthy volunteers ≥60 kg with creatinine clearance ≥60 mL/min.
^b tenofovir disoproxil fumarate.
^c 373 kcalories, 8.2 grams fat.

Didanosine Buffered Formulations

Tables 5 and 6 summarize the effects on AUC and C_{MAX}, with a 90% or 95% CI when available, following coadministration of buffered formulations of didanosine with a variety of drugs. Except as noted in table footnotes, the results of these studies may be expected to apply to VIDEX EC. For most of the listed drugs, no clinically significant pharmacokinetic interactions were noted. Clinical recommendations based on drug interaction studies for drugs in bold font are included in **PRECAUTIONS: Drug Interactions** and **DOSAGE AND ADMINISTRATION** (for tenofovir).

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 5: Results of Drug Interaction Studies with Buffered Formulations of Didanosine: Effects of Coadministered Drug on Didanosine Plasma AUC and C_{MAX} Values				
Drugs With Clinical Recommendations Regarding Coadministration (see PRECAUTIONS: Drug Interactions)				
Drug	Didanosine Dosage	n	AUC of Didanosine (95% CI)	C _{MAX} of Didanosine (95% CI)
allopurinol				
renally impaired, 300 mg/day	200 mg single dose	2	↑ 312%	↑ 232%
healthy volunteer, 300 mg/day for 7 days	400 mg single dose	14	↑ 113%	↑ 69%
ganciclovir , 1000 mg q8h, 2 h after didanosine	200 mg q12h	12	↑ 111%	NA
methadone , chronic maintenance dose	200 mg single dose	16, 10 ^a	↓ 57%	↓ 66%
tenofovir , ^b 300 mg once daily 1 h after didanosine	250 ^c or 400 mg once daily for 7 days	14	↑ 44% (31, 59%) ^d	↑ 28% (11, 48%) ^d
No Clinically Significant Interaction Observed				
Drug	Didanosine Dosage	n	AUC of Didanosine (95% CI)	C _{MAX} of Didanosine (95% CI)
ciprofloxacin, 750 mg q12h for 3 days, 2 h before didanosine	200 mg q12h for 3 days	8 ^e	↓ 16%	↓ 28%
indinavir, 800 mg single dose simultaneous	200 mg single dose	16	↔	↔
1 h before didanosine	200 mg single dose	16	↓ 17% (-27, -7%) ^d	↓ 13% (-28, 5%) ^d
ketoconazole, 200 mg/day for 4 days, 2 h before didanosine	375 mg q12h for 4 days	12 ^e	↔	↓ 12%
loperamide, 4 mg q6h for 1 day	300 mg single dose	12 ^e	↔	↓ 23%
metoclopramide, 10 mg single dose	300 mg single dose	12 ^e	↔	↑ 13%
ranitidine, 150 mg single dose, 2 h before didanosine	375 mg single dose	12 ^e	↑ 14%	↑ 13%
rifabutin, 300 or 600 mg/day for 12 days	167 or 250 mg q12h for 12 days	11	↑ 13% (-1, 27%)	↑ 17% (-4, 38%)
ritonavir, 600 mg q12h for 4 days	200 mg q12h for 4 days	12	↓ 13% (0, 23%)	↓ 16% (5, 26%)
stavudine, 40 mg q12h for 4 days	100 mg q12h for 4 days	10	↔	↔
sulfamethoxazole, 1000 mg single dose	200 mg single dose	8 ^e	↔	↔
trimethoprim, 200 mg single dose	200 mg single dose	8 ^e	↔	↑ 17% (-23, 77%)
zidovudine, 200 mg q8h for 3 days	200 mg q12h for 3 days	6 ^e	↔	↔

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Table 5: Results of Drug Interaction Studies with Buffered Formulations of Didanosine: Effects of Coadministered Drug on Didanosine Plasma AUC and C_{MAX} Values

↑ indicates increase.
↓ indicates decrease.
↔ indicates no change, or mean increase or decrease of <10%.
^a Parallel-group design; entries are subjects receiving combination and control regimens, respectively.
^b tenofovir disoproxil fumarate.
^c patients <60 kg with creatinine clearance ≥60 mL/min.
^d 90% CI.
^e HIV-infected patients.
NA Not available.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 6: Results of Drug Interaction Studies with Buffered Formulations of Didanosine: Effects of Didanosine on Coadministered Drug Plasma AUC and C_{MAX} Values					
<i>No Clinically Significant Interaction Observed</i>					
Drug	Didanosine Dosage	n	AUC of Coadministered Drug (95% CI)	C _{MAX} of Coadministered Drug (95% CI)	
dapsone, 100 mg single dose	200 mg q12h for 14 days	6 ^a	↔	↔	
delavirdine, 400 mg single dose					
simultaneous	125 or 200 mg q12h	12 ^a	↓ 32% ^b	↓ 53% ^b	
1 h before didanosine	125 or 200 mg q12h	12 ^a	↑ 20%	↑ 18%	
ganciclovir, 1000 mg q8h, 2 h after didanosine	200 mg q12h	12 ^a	↓ 21%	NA	
nelfinavir, 750 mg single dose, 1 h after didanosine	200 mg single dose	10 ^a	↑ 12%	↔	
ranitidine, 150 mg single dose, 2 h before didanosine	375 mg single dose	12 ^a	↓ 16%	↔	
ritonavir, 600 mg q12h for 4 days	200 mg q12h for 4 days	12	↔	↔	
stavudine, 40 mg q12h for 4 days	100 mg q12h for 4 days	10 ^a	↔	↑ 17%	
sulfamethoxazole, 1000 mg single dose	200 mg single dose	8 ^a	↓ 11% (-17, -4%)	↓ 12% (-28, 8%)	
tenofovir, ^c 300 mg once daily 1 h after didanosine	250 ^d or 400 mg once daily for 7 days	14	↔	↔	
trimethoprim, 200 mg single dose	200 mg single dose	8 ^a	↑ 10% (-9, 34%)	↓ 22% (-59, 49%)	
zidovudine, 200 mg q8h for 3 days	200 mg q12h for 3 days	6 ^a	↓ 10% (-27, 11%)	↓ 16.5% (-53, 47%)	
[↑] indicates increase. [↓] indicates decrease. [↔] indicates no change, or mean increase or decrease of <10%. ^a HIV-infected patients. ^b This result is probably related to the buffer and is not expected to occur with VIDEX EC. ^c tenofovir disoproxil fumarate. ^d patients <60 kg with creatinine clearance ≥60 mL/min. NA Not available.					


INDICATIONS AND USAGE

VIDEX EC (didanosine) in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in adults. (See Clinical Studies.)

Clinical Studies

Study AI454-152 was a 48-week, randomized, open-label study comparing VIDEX EC (400 mg once daily) plus stavudine (40 mg twice daily) plus nelfinavir (750 mg three times daily) to zidovudine (300 mg) plus lamivudine (150 mg) combination tablets twice daily plus nelfinavir (750 mg three times daily) in 511 treatment-naïve patients, with a mean CD4 cell count of 411 cells/mm³ (range 39 to 1105 cells/mm³) and a mean plasma HIV-1 RNA of 4.71 log₁₀ copies/mL (range 2.8 to 5.9 log₁₀ copies/mL) at baseline. Patients were primarily males (72%) and Caucasian (53%) with a mean age of 35 years (range 18 to 73 years). The percentages of patients with HIV RNA <400 and <50 copies/mL and outcomes of patients through 48 weeks are summarized in Figure 1 and Table 7, respectively.

Figure 1
Treatment Response Through Week 48*, AI454-152



*Percent of patients at each time point who have HIV RNA <400 or <50 copies/mL and do not meet any criteria for treatment failure (eg, virologic failure or discontinuation for any reason).

Outcome	Percent of Patients with HIV RNA <400 copies/mL (<50 copies/mL)	
	VIDEX EC + stavudine + nelfinavir n=258	zidovudine/lamivudine ^a + nelfinavir n=253
Responder ^{b,c}	55% (33%)	56% (33%)
Virologic failure ^d	22% (45%)	21% (43%)
Death or discontinued due to disease progression	1% (1%)	2% (2%)
Discontinued due to adverse event	6% (6%)	7% (7%)
Discontinued due to other reasons ^e	16% (16%)	15% (16%)

^a Zidovudine/lamivudine combination tablet.
^b Corresponds to rates at Week 48 in Figure 1.
^c Subjects achieved and maintained confirmed HIV RNA <400 copies/mL (<50 copies/mL) through Week 48.
^d Includes viral rebound at or before Week 48 and failure to achieve confirmed HIV RNA <400 copies/mL (<50 copies/mL) through Week 48.
^e Includes lost to follow-up, subject's withdrawal, discontinuation due to physician's decision, never treated, and other reasons.

CONTRAINDICATION

VIDEX EC (didanosine) is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any component of the formulation.

WARNINGS

1. Pancreatitis

FATAL AND NONFATAL PANCREATITIS HAVE OCCURRED DURING THERAPY WITH DIDANOSINE USED ALONE OR IN COMBINATION REGIMENS IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, REGARDLESS OF DEGREE OF IMMUNOSUPPRESSION. VIDEX EC SHOULD BE SUSPENDED IN PATIENTS WITH SIGNS OR SYMPTOMS OF PANCREATITIS AND DISCONTINUED IN

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

PATIENTS WITH CONFIRMED PANCREATITIS. PATIENTS TREATED WITH VIDEX EC IN COMBINATION WITH STAVUDINE, WITH OR WITHOUT HYDROXYUREA, MAY BE AT INCREASED RISK FOR PANCREATITIS.

When treatment with life-sustaining drugs known to cause pancreatic toxicity is required, suspension of VIDEX EC therapy is recommended. In patients with risk factors for pancreatitis, VIDEX EC should be used with extreme caution and only if clearly indicated. Patients with advanced HIV infection, especially the elderly, are at increased risk of pancreatitis and should be followed closely. Patients with renal impairment may be at greater risk for pancreatitis if treated without dose adjustment.

The frequency of pancreatitis is dose related. In phase 3 studies with buffered formulations of didanosine, incidence ranged from 1% to 10% with doses higher than are currently recommended and 1% to 7% with recommended dose.

2. Lactic Acidosis/Severe Hepatomegaly with Steatosis

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including didanosine and other antiretrovirals. A majority of these cases have been in women. Obesity and prolonged nucleoside exposure may be risk factors. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk (see **PRECAUTIONS: Pregnancy**). Particular caution should be exercised when administering VIDEX EC to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with VIDEX EC should be suspended in any patient who develops clinical or laboratory findings suggestive of symptomatic hyperlactatemia, lactic acidosis, or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

3. Retinal Changes and Optic Neuritis

Retinal changes and optic neuritis have been reported in patients taking didanosine. Periodic retinal examinations should be considered for patients receiving VIDEX EC. (See **ADVERSE REACTIONS**.)

4. Hepatic Impairment and Toxicity

It is unknown if hepatic impairment significantly affects didanosine pharmacokinetics. Therefore, these patients should be monitored closely for evidence of didanosine toxicity. The safety and efficacy of VIDEX EC have not been established in HIV-infected patients with significant underlying liver disease. During combination antiretroviral therapy, patients with preexisting liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities, including severe and potentially fatal hepatic adverse events, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.

Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV-infected patients treated with hydroxyurea and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. This combination should be avoided.

PRECAUTIONS

Dosing

VIDEX EC should be administered once daily on an empty stomach.

Peripheral Neuropathy

Peripheral neuropathy, manifested by numbness, tingling, or pain in the hands or feet, has been reported in patients receiving didanosine therapy. Peripheral neuropathy has occurred more frequently in patients with advanced HIV disease, in patients with a history of neuropathy, or in patients being treated with neurotoxic drug therapy, including stavudine. Peripheral neuropathy, which was severe in some cases, has been reported in HIV-infected patients receiving hydroxyurea in combination with antiretroviral agents, including didanosine, with or without stavudine (see **ADVERSE REACTIONS**).

Fat Redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including VIDEX EC. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jiroveci* pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

General

Patients with Renal Impairment

Patients with renal impairment (creatinine clearance <60 mL/min) may be at greater risk of toxicity from didanosine due to decreased drug clearance (see **CLINICAL PHARMACOLOGY**). A dose reduction is recommended in these patients (see **DOSAGE AND ADMINISTRATION**).

Hyperuricemia

Didanosine has been associated with asymptomatic hyperuricemia; treatment suspension may be necessary if clinical measures aimed at reducing uric acid levels fail.

Information for Patients (See Patient Information Leaflet)

Patients should be informed that a serious toxicity of didanosine, used alone and in combination regimens, is pancreatitis, which may be fatal.

Patients should also be aware that peripheral neuropathy, manifested by numbness, tingling, or pain in hands or feet, may develop during therapy with VIDEX EC

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

(didanosine). Patients should be counseled that peripheral neuropathy occurs with greatest frequency in patients with advanced HIV disease or a history of peripheral neuropathy, and that dose modification and/or discontinuation of VIDEX EC may be required if toxicity develops.

Patients should be informed that when didanosine is used in combination with other agents with similar toxicities, the incidence of adverse events may be higher than when didanosine is used alone. These patients should be followed closely.

Patients should be cautioned about the use of medications or other substances, including alcohol, that may exacerbate VIDEX EC toxicities.

VIDEX EC is not a cure for HIV infection, and patients may continue to develop HIV-associated illnesses, including opportunistic infection. Therefore, patients should remain under the care of a physician when using VIDEX EC. Patients should be advised that VIDEX EC therapy has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination. Patients should be informed that the long-term effects of VIDEX EC are unknown at this time.

Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time.

Drug Interactions (see also CLINICAL PHARMACOLOGY: Drug Interactions)

Drug interactions that have been established based on drug interaction studies are listed with the pharmacokinetic results in **CLINICAL PHARMACOLOGY: Drug Interactions** (Tables 3-6). The clinical recommendations based on the results of these studies are listed in Table 8.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 8: Established Drug Interactions Based on Studies with VIDEX EC or Studies with Buffered Formulations of Didanosine and Expected to Occur with VIDEX EC		
<i>Coadministration Not Recommended Based on Drug Interaction Studies (see CLINICAL PHARMACOLOGY: Drug Interactions for Magnitude of Interaction)</i>		
Drug	Effect	Clinical Comment
allopurinol	↑ didanosine concentration	Coadministration not recommended.
<i>Alteration in Dose or Regimen Recommended Based on Drug Interaction Studies (see CLINICAL PHARMACOLOGY: Drug Interactions for Magnitude of Interaction)</i>		
Drug	Effect	Clinical Comment
ganciclovir	↑ didanosine concentration	Appropriate doses for this combination, with respect to efficacy and safety, have not been established.
methadone	↓ didanosine concentration	Appropriate doses for this combination, with respect to efficacy and safety, have not been established.
tenofovir disoproxil fumarate	↑ didanosine concentration	A dose reduction of VIDEX EC to 250 mg (adults weighing ≥60 kg with creatinine clearance ≥60 mL/min) or 200 mg (adults weighing <60 kg with creatinine clearance ≥60 mL/min) once daily taken together with tenofovir and a light meal (≤400 calories and ≤20% fat) or in the fasted state is recommended. Patients should be monitored for didanosine-associated toxicities and clinical response (see below).
↑ indicates increase.		
↓ indicates decrease.		

Coadministration of VIDEX EC with drugs that are known to cause pancreatitis may increase the risk of this toxicity (see WARNINGS: Pancreatitis). Predicted drug interactions with VIDEX EC are listed in Table 9.

NDA 20-154/S-049
 NDA 20-155/S-038
 NDA 20-156/S-039
 NDA 21-183/S-015

Table 9: Predicted Drug Interactions with VIDEX EC		
Drug or Drug Class	Effect	Clinical Comment
Drugs that may cause pancreatic toxicity	↑ risk of pancreatitis	Use only with extreme caution. ^a
Neurotoxic drugs	↑ risk of neuropathy	Use with caution. ^b
Ribavirin	↑ risk of toxicity	Ribavirin has been shown <i>in vitro</i> to increase intracellular triphosphate levels of didanosine. Coadministration is not recommended (see below).
<p>↑ indicates increase.</p> <p>^a Only if other drugs are not available and if clearly indicated. If treatment with life-sustaining drugs that cause pancreatic toxicity is required, suspension of VIDEX EC is recommended (see WARNINGS: Pancreatitis).</p> <p>^b See PRECAUTIONS: Peripheral Neuropathy.</p>		

Nucleoside/nucleotide analogues

Tenofovir disoproxil fumarate. Exposure to didanosine is increased when coadministered with tenofovir (see Tables 3, 5, and 8). **Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy. Coadministration of tenofovir with VIDEX EC should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response. VIDEX EC should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop (see WARNINGS).** Administration of reduced doses of VIDEX EC with tenofovir and a light meal resulted in didanosine exposures (AUC) similar to the recommended doses of VIDEX EC given alone in the fasted state (see Table 3). Therefore, when administered with tenofovir, a dose reduction of VIDEX EC to 250 mg (adults weighing ≥60 kg with creatinine clearance ≥60 mL/min) or 200 mg (adults weighing <60 kg with creatinine clearance ≥60 mL/min) once daily is recommended, and both drugs may be taken together with a light meal (≤400 calories, ≤20% fat) or in the fasted state (see **DOSAGE AND ADMINISTRATION**). Coadministration of didanosine with food decreases didanosine concentrations. Thus, although not studied, it is possible that coadministration with heavier meals could reduce didanosine concentrations further.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Ribavirin. Exposure to the active metabolite of didanosine (dideoxyadenosine 5'-triphosphate) is increased when didanosine is coadministered with ribavirin (see Table 9). Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. Coadministration of didanosine and ribavirin is not recommended.

Carcinogenesis and Mutagenesis

Lifetime carcinogenicity studies were conducted in mice and rats for 22 and 24 months, respectively. In the mouse study, initial doses of 120, 800, and 1200 mg/kg/day for each sex were lowered after 8 months to 120, 210, and 210 mg/kg/day for females and 120, 300, and 600 mg/kg/day for males. The two higher doses exceeded the maximally tolerated dose in females and the high dose exceeded the maximally tolerated dose in males. The low dose in females represented 0.68-fold maximum human exposure and the intermediate dose in males represented 1.7-fold maximum human exposure based on relative AUC comparisons. In the rat study, initial doses were 100, 250, and 1000 mg/kg/day, and the high dose was lowered to 500 mg/kg/day after 18 months. The upper dose in male and female rats represented 3-fold maximum human exposure.

Didanosine induced no significant increase in neoplastic lesions in mice or rats at maximally tolerated doses.

Didanosine was positive in the following genetic toxicology assays: 1) the *Escherichia coli* tester strain WP2 uvrA bacterial mutagenicity assay; 2) the L5178Y/TK+/- mouse lymphoma mammalian cell gene mutation assay; 3) the *in vitro* chromosomal aberrations assay in cultured human peripheral lymphocytes; 4) the *in vitro* chromosomal aberrations assay in Chinese Hamster Lung cells; and 5) the BALB/c 3T3 *in vitro* transformation assay. No evidence of mutagenicity was observed in an Ames *Salmonella* bacterial mutagenicity assay or in rat and mouse *in vivo* micronucleus assays.

Pregnancy, Reproduction, and Fertility

Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 12 and 14.2 times the estimated human exposure (based upon plasma levels), respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to didanosine. At approximately 12 times the estimated human exposure, didanosine was slightly toxic to female rats and their pups during mid and late lactation. These rats showed

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

reduced food intake and body weight gains but the physical and functional development of the offspring was not impaired and there were no major changes in the F2 generation. A study in rats showed that didanosine and/or its metabolites are transferred to the fetus through the placenta. Animal reproduction studies are not always predictive of human response.

There are no adequate and well-controlled studies of didanosine in pregnant women. Didanosine should be used during pregnancy only if the potential benefit justifies the potential risk.

Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. It is unclear if pregnancy augments the risk of lactic acidosis/hepatic steatosis syndrome reported in nonpregnant individuals receiving nucleoside analogues (see **WARNINGS: Lactic Acidosis/Severe Hepatomegaly with Steatosis**). **The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk.** Health care providers caring for HIV-infected pregnant women receiving didanosine should be alert for early diagnosis of lactic acidosis/hepatic steatosis syndrome.

Antiretroviral Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women exposed to didanosine and other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.

Nursing Mothers

The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV. A study in rats showed that following oral administration, didanosine and/or its metabolites were excreted into the milk of lactating rats. It is not known if didanosine is excreted in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, **mothers should be instructed not to breast-feed if they are receiving VIDEX EC (didanosine).**

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Pediatric Use

The safety and efficacy of VIDEX EC in pediatric patients have not been established. Please consult the complete prescribing information for VIDEX (didanosine) Chewable/Dispersible Buffered Tablets and Pediatric Powder for Oral Solution for dosage and administration of didanosine to pediatric patients.

Geriatric Use

In an Expanded Access Program using a buffered formulation of didanosine for the treatment of advanced HIV infection, patients aged 65 years and older had a higher frequency of pancreatitis (10%) than younger patients (5%) (see **WARNINGS**). Clinical studies of didanosine, including those for VIDEX EC, did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently than younger subjects. Didanosine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. In addition, renal function should be monitored and dosage adjustments should be made accordingly (see **DOSAGE AND ADMINISTRATION: Dose Adjustment**).

ADVERSE REACTIONS

A SERIOUS TOXICITY OF DIDANOSINE IS PANCREATITIS, WHICH MAY BE FATAL (see **WARNINGS**). OTHER IMPORTANT TOXICITIES INCLUDE LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS; RETINAL CHANGES AND OPTIC NEURITIS; AND PERIPHERAL NEUROPATHY (see **WARNINGS** and **PRECAUTIONS**).

When didanosine is used in combination with other agents with similar toxicities, the incidence of these toxicities may be higher than when didanosine is used alone. Thus, patients treated with VIDEX EC in combination with stavudine, with or without hydroxyurea, may be at increased risk for pancreatitis and hepatotoxicity, which may be fatal, and severe peripheral neuropathy (see **WARNINGS and **PRECAUTIONS**).**

Selected clinical adverse events that occurred in a study of VIDEX EC in combination with other antiretroviral agents are provided in Table 10.

Table 10: Selected Clinical Adverse Events, Study AI454-152^a		
Adverse Events	Percent of Patients ^b	
	VIDEX EC + stavudine + nelfinavir n=258	zidovudine/lamivudine ^c + nelfinavir n=253
Diarrhea	57	58
Peripheral Neurologic Symptoms/Neuropathy	25	11
Nausea	24	36
Headache	22	17
Rash	14	12
Vomiting	14	19
Pancreatitis (see below)	<1	*

^a Median duration of treatment was 62 weeks in the VIDEX EC + stavudine + nelfinavir group and 61 weeks in the zidovudine/lamivudine + nelfinavir group.

^b Percentages based on treated patients.

^c Zidovudine/lamivudine combination tablet.

* This event was not observed in this study arm.

In clinical trials using a buffered formulation of didanosine, pancreatitis resulting in death was observed in one patient who received didanosine plus stavudine plus nelfinavir, one patient who received didanosine plus stavudine plus indinavir, and 2 of 68 patients who received didanosine plus stavudine plus indinavir plus hydroxyurea. In an early access program, pancreatitis resulting in death was observed in one patient who received VIDEX EC plus stavudine plus hydroxyurea plus ritonavir plus indinavir plus efavirenz (see WARNINGS).

The frequency of pancreatitis is dose related. In phase 3 studies with buffered formulations of didanosine, incidence ranged from 1% to 10% with doses higher than are currently recommended and 1% to 7% with recommended dose.

Selected laboratory abnormalities that occurred in a study of VIDEX EC in combination with other antiretroviral agents are shown in Table 11.

Table 11: Selected Laboratory Abnormalities, Study AI454-152^a

Parameter	Percent of Patients ^b			
	VIDEX EC + stavudine + nelfinavir n=258		zidovudine/lamivudine ^c + nelfinavir n=253	
	Grades 3-4 ^d	All Grades	Grades 3-4 ^d	All Grades
SGOT (AST)	5	46	5	19
SGPT (ALT)	6	44	5	22
Lipase	5	23	2	13
Bilirubin	<1	9	<1	3

^a Median duration of treatment was 62 weeks in the VIDEX EC + stavudine + nelfinavir group and 61 weeks in the zidovudine/lamivudine + nelfinavir group.
^b Percentages based on treated patients.
^c Zidovudine/lamivudine combination tablet.
^d >5 x ULN for SGOT and SGPT, ≥2.1 x ULN for lipase, and ≥2.6 x ULN for bilirubin (ULN = upper limit of normal).

Observed During Clinical Practice

The following events have been identified during postapproval use of didanosine buffered formulations. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to their seriousness, frequency of reporting, causal connection to didanosine, or a combination of these factors.

Body as a Whole – abdominal pain, alopecia, anaphylactoid reaction, asthenia, chills/fever, pain, and redistribution/accumulation of body fat (see **PRECAUTIONS: Fat Redistribution**).

Digestive Disorders – anorexia, dyspepsia, and flatulence.

Exocrine Gland Disorders – pancreatitis (including fatal cases) (see **WARNINGS**), sialoadenitis, parotid gland enlargement, dry mouth, and dry eyes.

Hematologic Disorders – anemia, leukopenia, and thrombocytopenia.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Liver – symptomatic hyperlactatemia/lactic acidosis and hepatic steatosis (see **WARNINGS**); hepatitis and liver failure.

Metabolic Disorders – diabetes mellitus, elevated serum alkaline phosphatase level, elevated serum amylase level, elevated serum gamma-glutamyltransferase level, elevated serum uric acid level, hypoglycemia, and hyperglycemia.

Musculoskeletal Disorders – myalgia (with or without increases in creatine kinase), rhabdomyolysis including acute renal failure and hemodialysis, arthralgia, and myopathy.

Ophthalmologic Disorders – Retinal depigmentation and optic neuritis (see **WARNINGS**).

OVERDOSAGE

There is no known antidote for didanosine overdose. In phase 1 studies, in which buffered formulations of didanosine were initially administered at doses ten times the currently recommended dose, toxicities included: pancreatitis, peripheral neuropathy, diarrhea, hyperuricemia, and hepatic dysfunction. Didanosine is not dialyzable by peritoneal dialysis, although there is some clearance by hemodialysis (see **CLINICAL PHARMACOLOGY: Pharmacokinetics**).

DOSAGE AND ADMINISTRATION

Dosage

Adults

VIDEX EC (didanosine) should be administered on an empty stomach.

VIDEX EC Delayed-Release Capsules should be swallowed intact.

The recommended daily dose is dependent on body weight and is administered as one capsule given on a once-daily schedule as outlined in Table 12.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Patient Weight	Dosage
≥60 kg	400 mg once daily
<60 kg	250 mg once daily

Pediatric Patients

VIDEX EC has not been studied in pediatric patients. Please consult the complete prescribing information for VIDEX (didanosine) Chewable/Dispersible Buffered Tablets and Pediatric Powder for Oral Solution for dosage and administration of didanosine to pediatric patients.

Dose Adjustment

Clinical and laboratory signs suggestive of pancreatitis should prompt dose suspension and careful evaluation of the possibility of pancreatitis. VIDEX EC use should be discontinued in patients with confirmed pancreatitis (see WARNINGS and PRECAUTIONS: Drug Interactions).

Based on data with buffered didanosine formulations, patients with symptoms of peripheral neuropathy may tolerate a reduced dose of VIDEX EC after resolution of the symptoms of peripheral neuropathy upon drug interruption. If neuropathy recurs after resumption of VIDEX EC, permanent discontinuation of VIDEX EC should be considered.

Concomitant Therapy

Tenofovir disoproxil fumarate. A dose reduction of VIDEX EC to 250 mg (adults weighing ≥60 kg with creatinine clearance ≥60 mL/min) or 200 mg (adults weighing <60 kg with creatinine clearance ≥60 mL/min) once daily taken together with tenofovir and a light meal (≤400 kcalories, ≤20% fat) or in the fasted state is recommended. **The appropriate dose of VIDEX EC coadministered with tenofovir in patients with creatinine clearance <60 mL/min has not been established. (See CLINICAL PHARMACOLOGY: Drug Interactions and PRECAUTIONS: Drug Interactions.)**

Renal Impairment

Dosing recommendations for VIDEX EC and VIDEX buffered formulations are different for patients with renal impairment. Please consult the complete prescribing information on administration of VIDEX (didanosine) buffered formulations to patients with renal impairment.

In adult patients with impaired renal function, the dose of VIDEX EC should be adjusted to compensate for the slower rate of elimination. The recommended doses and dosing intervals of VIDEX EC in adult patients with renal insufficiency are presented in Table 13.

Table 13: Recommended Dosage of VIDEX EC in Renal Impairment by Body Weight^a		
Creatinine Clearance (mL/min)	Dosage	
	≥60 kg	<60 kg
≥60	400 once daily	250 once daily
30-59	200 once daily	125 once daily
10-29	125 once daily	125 once daily
<10	125 once daily	^b

^a Based on studies using a buffered formulation of didanosine.

^b Not suitable for use in patients <60 kg with CL_{cr} <10 mL/min. An alternate formulation of didanosine should be used.

Patients Requiring Continuous Ambulatory Peritoneal Dialysis (CAPD) or Hemodialysis

For patients requiring CAPD or hemodialysis, follow dosing recommendations for patients with creatinine clearance less than 10 mL/min, shown in Table 13. It is not necessary to administer a supplemental dose of didanosine following hemodialysis.

Hepatic Impairment and Toxicity: See WARNINGS.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

HOW SUPPLIED

VIDEX[®] EC (didanosine) Delayed-Release Capsules are white, opaque capsules that are packaged in bottles with child-resistant closures as described in Table 14.

Table 14: VIDEX EC Delayed-Release Capsules	
125 mg capsule imprinted with BMS 125 mg 6671 in Tan NDC No. 0087-6671-17	30 capsules/bottle
200 mg capsule imprinted with BMS 200 mg 6672 in Green NDC No. 0087-6672-17	30 capsules/bottle
250 mg capsule imprinted with BMS 250 mg 6673 in Blue NDC No. 0087-6673-17	30 capsules/bottle
400 mg capsule imprinted with BMS 400 mg 6674 in Red NDC No. 0087-6674-17	30 capsules/bottle

The capsules should be stored in tightly closed containers at 25° C (77° F). Excursions between 15° and 30° C (59° and 86° F) are permitted [see USP Controlled Room Temperature].

HANDLING AND DISPOSAL

Disposal options include incineration, landfill, or sewer as dictated by specific circumstances and relevant national, state, and local regulations.

US Patent Nos: 4,861,759, 5,254,539, 5,616,566, and 5,880,106 (didanosine).

Patent also Pending (didanosine capsules).

Bristol-Myers Squibb Virology
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA

1196180A2

Revised July 2006

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

PATIENT INFORMATION

Rx only

VIDEX[®] EC

(generic name = **didanosine** also known as **ddI**)

VIDEX[®] EC (didanosine) Delayed-Release Capsules
Enteric-Coated Beadlets

What is VIDEX EC?

VIDEX EC (pronounced *VY dex ee see*) is a prescription medicine used in combination with other drugs to treat adults who are infected with HIV (the human immunodeficiency virus, the virus that causes AIDS). VIDEX EC belongs to a class of drugs called nucleoside analogues. By reducing the growth of HIV, VIDEX EC helps your body maintain its supply of CD4 cells, which are important for fighting HIV and other infections.

VIDEX EC will not cure your HIV infection. At present there is no cure for HIV infection. Even while taking VIDEX EC, you may continue to have HIV-related illnesses, including infections with other disease-producing organisms. Continue to see your doctor regularly and report any medical problems that occur.

VIDEX EC does not prevent a patient infected with HIV from passing the virus to other people. To protect others, you must continue to practice safe sex and take precautions to prevent others from coming in contact with your blood and other body fluids.

There is limited information on the antiviral response of long-term use of VIDEX EC.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

In VIDEX EC, an enteric coating is used to protect the medicine while it is in your stomach since stomach acids can break it down. The enteric coating dissolves when the medicine reaches your small intestine.

Who should not take VIDEX EC?

Do not take VIDEX EC if you are allergic to any of its ingredients, including its active ingredient, didanosine, and the inactive ingredients. (See **Inactive Ingredients** at the end of this leaflet.) Tell your doctor if you think you have had an allergic reaction to any of these ingredients.

Because it has only been studied in adults, VIDEX EC is not recommended for children.

How should I take VIDEX EC?

How should I store it?

VIDEX EC should only be taken once daily. Your doctor will determine your dose based on your body weight, kidney and liver function, other medicines you are taking, and any side effects that you may have had with VIDEX EC or other medicines. Take VIDEX EC **on an empty stomach. Do not take VIDEX EC with food.** Swallow the capsule whole; do not open it. Try not to miss a dose, but if you do, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule.

Store capsules in a tightly closed container at room temperature away from heat and out of the reach of children and pets.

If you have kidney disease: If your kidneys are not working properly, your doctor will need to do regular tests to check how they are working while you take VIDEX EC. Your doctor may also lower your dosage of VIDEX EC.

What should I do if someone takes an overdose of VIDEX EC?

If someone may have taken an overdose of VIDEX EC, get medical help right away. Contact their doctor or a poison control center.

What should I avoid while taking VIDEX EC?

Alcohol. Do not drink alcohol while taking VIDEX EC since alcohol may increase your risk of pancreatitis (pain and inflammation of the pancreas) or liver damage.

Other medicines. Other medicines, including those you can buy without a prescription, may interfere with the actions of VIDEX EC or may increase the possibility or severity of side effects. **Do not take any medicine, vitamin supplement, or other health preparation without first checking with your doctor.**

Pregnancy. It is not known if VIDEX EC can harm a human fetus. Also, pregnant women have experienced serious side effects when taking didanosine (the active ingredient in VIDEX EC) in combination with ZERIT (stavudine), also known as d4T, and other HIV medicines. VIDEX EC should be used during pregnancy only after discussion with your doctor. **Tell your doctor if you become pregnant or plan to become pregnant while taking VIDEX EC.**

Nursing. Studies have shown didanosine (the active ingredient in VIDEX EC) is in the breast milk of animals getting the drug. It may also be in human breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers **not** breast-feed. This should reduce the risk of passing HIV infection to their babies and the potential for serious adverse reactions in nursing infants. Therefore, do not nurse a baby while taking VIDEX EC.

What are the possible side effects of VIDEX EC?

Pancreatitis. Pancreatitis is a dangerous inflammation of the pancreas that may cause death. ***Tell your doctor right away if you develop stomach pain, nausea, or vomiting. These can be signs of pancreatitis.*** Before starting VIDEX EC therapy, let your doctor know if you have ever had pancreatitis. This condition is more likely to happen in people who have had it before. It is also more likely in people with advanced HIV disease. However, it can occur at any stage of HIV disease. It may be more common in patients with kidney problems, those who drink alcohol, and those who are also treated with stavudine or hydroxyurea. If you get pancreatitis, your doctor will tell you to stop taking VIDEX EC.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Lactic acidosis, severe liver enlargement, and liver failure, including deaths, have been reported among patients taking VIDEX EC (including pregnant women). Symptoms that may indicate a liver problem are:

- feeling very weak, tired, or uncomfortable,
- unusual or unexpected stomach discomfort,
- feeling cold,
- feeling dizzy or lightheaded,
- suddenly developing a slow or irregular heartbeat.

Lactic acidosis is a medical emergency that must be treated in a hospital.

If you notice any of these symptoms or if your medical condition changes, stop taking VIDEX EC and **call your doctor right away**. Women, overweight patients, and those who have been treated for a long time with other medicines used to treat HIV infection are more likely to develop lactic acidosis. Your doctor should check your liver function periodically while you are taking VIDEX EC. You should be especially careful if you have a history of heavy alcohol use or a liver problem.

Vision changes. VIDEX EC may affect the nerves in your eyes. Because of this, you should have regular eye examinations. You should also report any changes in vision to your doctor right away. This includes, for example, seeing colors abnormally or blurred vision.

Peripheral neuropathy. This is a problem with the nerves in your hands or feet. The nerve problem may be serious. ***Tell your doctor right away if you have continuing numbness, tingling, or pain in the feet or hands.***

Before starting VIDEX EC therapy, let your doctor know if you have ever had peripheral neuropathy. This condition is more likely to happen in people who have had it before. It is also more likely in patients taking medicines that affect the nerves and in people with advanced HIV disease. However, it can occur at any stage of HIV disease. If you get peripheral neuropathy, your doctor will tell you to stop taking VIDEX EC. After stopping VIDEX EC, the symptoms may get worse for a short time and then get better. Once symptoms of peripheral neuropathy go away completely, you and your doctor should decide if starting VIDEX EC is right for you. If so, you might be started at a lower dose.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Special note about other medicines. If you take VIDEX EC along with other medicines with similar side effects, you may increase the chance of having these side effects. For example, using VIDEX EC in combination with other medicines that may cause pancreatitis, peripheral neuropathy, or liver problems (including stavudine and hydroxyurea) may increase your chance of having these side effects.

Other side effects: The most common side effects in adults taking VIDEX EC in combination with other HIV drugs included diarrhea, nausea, headache, vomiting, and rash.

Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck (“buffalo hump”), breast, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known at this time.

Inactive Ingredients:

Carboxymethylcellulose sodium 12, diethyl phthalate, methacrylic acid copolymer, sodium hydroxide, sodium starch glycolate, talc, colloidal silicon dioxide, gelatin, sodium lauryl sulfate, and titanium dioxide.

This medicine was prescribed for your particular condition. Do not use VIDEX EC for another condition or give it to others. Keep VIDEX EC and all medicines out of the reach of children. Throw away VIDEX EC when it is outdated or no longer needed by flushing it down the toilet or pouring it down the sink.

This summary does not include everything there is to know about VIDEX EC. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. If you have questions or concerns, or want more information about VIDEX EC, your physician and pharmacist have the complete prescribing information upon which this leaflet is based. You may want to read it and discuss it with your doctor or other healthcare professional. Remember, no written summary can replace careful discussion with your doctor.

Bristol-Myers Squibb Virology
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA

This Patient Information Leaflet has been approved by the U.S. Food and Drug Administration.

NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

1196180A2

Revised July 2006

Based on package insert dated July 2006

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-154 / S-049

20-155 / S-038

20-156 / S-039

20-183 / S-015

ADMINISTRATIVE and CORRESPONDENCE **DOCUMENTS**



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville, MD 20857

**Division of Antiviral Products (DAVP)
Consumer Safety Officer Labeling Review-Changes Being Effected Supplements**

Application Numbers: NDA 20-154/S-049
NDA 20-155/S-038
NDA 20-156/S-039
NDA 21-183/S-015

Name of Drugs: Videx[®] (didanosine) Chewable/Dispersible Buffered Tablets 25 mg,
50 mg, 100 mg, 150mg, and 200 mg
Videx[®] (didanosine) Buffered Powder for Oral Solution 45 mg, 67mg,
100 mg, 167 mg, 250 mg, and 375 mg
Videx[®] (didanosine) Pediatric Powder for Oral Solution 2mg/bottle,
and 4gm/bottle
Videx[®] EC (didanosine) Delayed Release Capsules 125 mg, 200 mg, 250 mg,
and 400 mg

Applicant: Bristol-Myers Squibb Company
5 Research Parkway
Signature 91 Bldg., 3SIG-513
Wallingford, CT 06492

Original Submission Date: January 27, 2006
Original Receipt Date: January 30, 2006
Amendment Submission Date: July 31, 2006
Amendment Receipt Date: August 1, 2006

MATERIALS REVIEWED:

Labeling Supplements-Changes Being Effected (CBE) amended on July 31, 2006 were compared to the most recent approved package insert and patient package insert (NDAs 20-154/S-044, 20-155/S-034, 20-156/S-035, and 21-183/S-010 approved on January 21, 2004) of Videx[®] and Videx[®] EC. **Please note that Bristol-Myers Squibb (BMS) first**

submitted these labeling supplements on December 1, 2005 but due to Structured Product Labeling (SPL) errors these were cancelled and resubmitted on January 27, 2006. In addition, on July 6, 2006, the Division recommended that BMS amend these labeling supplements to incorporate 2 recommendations (1 major and 1 minor). On July 31, 2006, BMS amended these labeling supplements and complied with the 2 recommendations. Also, the Division's letter requesting labeling changes for all manufactures of antiretroviral agents for the treatment of HIV-1 infection dated April 11, 2005 was used.

BACKGROUND AND SUMMARY:

On April 11, 2005 DAVP issued a letter to BMS requesting that all manufactures of antiretroviral agents for the treatment of HIV-1 infection submit CBE supplements to include a statement regarding immune reconstitution syndrome in the PRECAUTIONS section of the label. Labeling changes which incorporated a statement regarding immune reconstitution syndrome in the PRECAUTIONS section in a draft proposal of the package insert (PI) for Videx[®] and Videx[®] EC were submitted and amended on January 27, 2006 and July 31, 2006 and received on January 30, 2006 and August 1, 2006, respectively. In addition, BMS included the additional labeling changes in a draft proposal of the PI and the patient package insert (PPI) for Videx[®] and Videx[®] EC:

- Adding a warning statement regarding patients with preexisting liver disease
- Adding a warning/precaution statement regarding adverse events when coadministered with hydroxyurea
- Deleting Extra Strength Maalox[®] from the Method of Preparation (**only for Videx[®]**)
- Revising the cautionary statement for tenofovir/didanosine coadministration to add monitoring for clinical response

There are minor text changes for the PPI of Videx. Minor editorial changes are also addressed.

There are no text changes to the PPI of Videx[®] EC. There are only editorial revisions.

REVIEW OF PACKAGE INSERT, VIDEX[®]:

See the attached annotated document comparison.

Details of major changes:

1. PRECAUTIONS

Addition of the following statement:

Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including VIDEX. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Monica Zeballos
8/18/2006 01:33:15 PM
CSO

Virginia Behr
8/18/2006 02:08:30 PM
CSO